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SYNOPSIS
1The research work incorporated in the thesis with the title “STUDIES ON
HETEROCYCLIC COMPOUNDS OF THERAPEUTIC IMPORTANCE” has been
described as under.
[A]  STUDIES ON CHALCONES
[B]  STUDIES ON PYRAZOLES
[A] STUDIES ON CHALCONES
The chalcones containing an active keto-ethylenic linkage are well known
intermediates in the synthesis of heterocyclic compounds. They are exhibiting various
biological activities such as antibacterial, analgesic, anthelmintic, antiinflammatory,
antitubercular, antifungal, antimicrobial etc.
The chalcones are good intermediate for the preparation of numerous heterocyclic
compounds like pyrazolines, oxopyrimidine, thiopyrimidine, cyanopyran barbitones,
aminopyrimidine, cyanopyridine, and thiosemicarbazones which have been described as
following parts.
PART-I : STUDIES ON PYRAZOLINE DERIVATIVES
Pyrazolines have played important role in medicinal chemistry. We have synthesise
pyrazoline as under.
SECTION–I     :  Preparation    and   biological   evaluation   of   1,N-Phenyl-3-
        β-pyridyl-4-formyl pyrazole
Pyrazole aldehyde of type (I) was prepared by the action of DMF and POCl3 on






2SECTION–II     :  Synthesis and biological evaluation of 1-Aryl-3-(1’,N-phenyl–
                              3’-β-pyridyl-pyrazol-4’-yl)-2-propen-1-ones
The chalcone derivatives of type (II) have been prepared by the condensation
of 1,N-phenyl-3-β-pyridyl-4-formyl pyrazole with different aryl ketones in presence
of  40% NaOH.
SECTION–III     :  Synthesis  and biological evaluation of 1,N-Phenyl-3-aryl-5
           (1’,N-phenyl-3’-β-pyridyl-pyrazol-4’-yl)-pyrazolines
The pyrazoline derivatives of type (III) have been prepared by the reaction of
type (II) with phenyl hydrazine in presence of basic catalyst like piperidine.
Type  (II) R=Aryl













PART-II : STUDIES ON PYRIMIDINES
Pyrimidine derivatives have been reported to possess various biological activities
like antitubercular, antifungal, herbicidal, diuretic etc. Led by these considerations, it
was contemplated to synthesise some pyrimidine derivatives which have been described
as under.
SECTION–I     :     Synthesis  and biological evaluation  of  6-Aryl-4-(1’,N-
phenyl-3’-β-pyridyl-1H-pyrazol-4’-yl)-2,3-dihydropyrimidine-
2-thiones
Thiopyrimidines of type (IV) have been synthesized by the condensation of
chalcones of type (II) with thiourea in presence of alcoholic KOH.
SECTION–II  :     Synthesis and biological evaluation of 6-Aryl-4-(1’,N-phenyl-
      3’-β-pyridyl-1H-pyrazol-4’-yl)-2,3-dihydropyrimidine-2-ones
Type  (IV) R=Aryl

















4Pyrimidinones of type (V) have been synthesized by the condensation of chalcones
of type(II) with urea in presence of alcoholic KOH.
PART-III : STUDIES ON CYANOPYRANS
Cyanopyran derivatives have been reported to possess various pharmacological
activities such as antibacterial, antifilarial, antifungal, anticoagulant etc. Keeping this in
view to achieve better potency different types of cyanopyran derivatives have been
described as under.
SECTION–I    :    Synthesis and biological evaluation of 2-Amino-6-Aryl-3-cyano-
                          4-(1’,N-phenyl-3’-β-pyridyl-pyrazol-4’-yl)-4H-pyrans
Cyanopyrans of type (VI) have been synthesized by the condensation of chalcones
of type (II) with malononitrile in pyridine.
PART-IV   : STUDIES ON BARBITONES
Barbitones plays a vital role owing to their wide range of biological activities like
antitumor, antiinflammatory, antitubercular and antidiabetic etc. Synthesis of some novel
barbitone derivatives have been undertaken in order to assess their pharmacological
profile, which have been described under.









SECTION–I     :  Synthesis and biological evaluation of 5-[1-Aryl-3-(1’,N-phenyl-
       3’-β-pyridyl-1H-pyrazol-4’-yl)-prop-2-enylidene]pyrimidine-
                          2,4,6 (1H,3H,5H)-triones
Barbitone derivatives of type (VII) have been prepared by the condensation of
type(II) with barbituric acid.
PART-V   : STUDIES ON AMINOPYRIMIDINES
It has been reported that pyrimidine derivatives are associated with various
biological activities like antifungal, antitubercular, antibacterial, herbicidal etc. These
valid observations led us to synthesise aminopyrimidine derivatives which have been
described as under.
SECTION–I     :  Synthesis  and  biological  evaluation  of  2-Amino-4-aryl-6-
       (1’,N-phenyl-3’-β-pyridyl-1H-pyrazol-4’-yl)pyrimidines
Type  (VIII)       R=Aryl
















6The compounds of type (VIII) have been synthesized by the condensation of
type (II) with guanidine hydrochloride in basic media.
PART-VI   : STUDIES ON CYANOPYRIDINES
Cyanopyridine plays a vital role owing to their wide range of biological activities
such as antihypertensive, antibacterial, antidiabetic and anticholestemic. They have been
also used as dyes for cotton and polyester fabrics, it appeared of interest to design and
synthesise cyanopyridine derivatives, which have been described as under.
SECTION–I     :  Synthesis and biological  evaluation  of 2-Amino-3-cyano-4-
                           (1’,N-phenyl-3’-β-pyridyl–pyrazol-4’-yl)-6-aryl-pyridines
2-Amino-3-cyanopyridines of type(IX) have been under taken by the
condensation of chalcones of type(II) with ammonium acetate and malononitrile.
PART-VII   : STUDIES ON THIOSEMICARBAZONES
The study of thiosemicarbazone as valuable drug for the diseases like tuberculosis,
cancer, diabetes, malaria and leprosy is well known. In view of these facts, it was
contemplated to synthesise thiosemicarbazone derivatives which have been described
as under.








7SECTION–I     :  Synthesis and biological evaluation of 1-Aryl-3-(1’,N-phenyl-
        3’-β-pyridyl-pyrazol-4’-yl)-2-propene-1-thiosemicarbazones
The thiosemicarbazones of type(X) have been prepared by the condensation of
chalcones of type (II) with thiosemicabazide.
SECTION–II     :  Microwave induced an expenditous synthesis of 1-Aryl-3-
    (1’ ,N-phenyl-3’-β-pyridyl-pyrazol-4’-yl) -2-propene-1-
      thiosemicarbazones
In recent years, MORE (Microwave Induced Organic Reaction Enhancement)
technique has become very popular due to substantial reduction in reaction time,
operational simplicity and formation of cleaner reaction products. Keeping these facts in
view, we have synthesised thiosemicarbazone derivatives using microwave irradiation.
Type  (X) R=Aryl















8The thiosemicarbazones of type(X) have been prepared using microwave
irradiation of chalcones of type (II) with thiosemicabazide.
 [B]  STUDIES ON PYRAZOLES
Pyrazole derivatives are associated with broad spectrum of pharmacological
activities like antitubercular, antimicrobial, hypnotics, antiinflammatory, antitumor, plant
growth regulators and are also used as herbicidal and insecticidal.
Looking to the diversified biological activities, it appeared of interest to synthesise
some acetonitrile, azomethine and thiazolidinone.
PART-VIII   : STUDIES ON α-ARYLAMINONITRILES
Nitriles have been reported to be active as antibacterial, antifungal, antipyretic
and antimalarial etc. In order to achieve better biological activity, we have synthesised
some new nitrile derivatives bearing pyrazoline nucleus, which is described as under.
SECTION–I     :  Preparation and biological evaluation of α-Arylamino-1,N-
       phenyl-3-β-pyridyl-pyrazol-4-yl-acetonitriles
Nitriles of type(XI) have been synthesized by the condensation of different
aromatic amines with type(I) by using potassium cyanide in presence of glacial acetic
acid at 0-5o C.







9PART-IX   :  STUDIES ON N-ARYL-1,N-PHENYL-3-β-PYRIDYL-4-YL-
         AZOMETHINES
Azomethine derivatives represent one of the modest classes of compounds
possessing wide range of therapeutic activities, such as antimicrobial, antimalarial,
antibacterial. With a view to getting better therapeutic agents and to evaluate its
pharmacological profile, different type of azomethine derivatives have been prepared,
and reduction as under.
SECTION–I : Synthesis  and  biological  evaluation  of  N-Aryl-1,N-phenyl-3-β-
   pyridyl-4-yl-azomethines
The azomethines of type (XII) have been prepared by the condensation of type
(I) with different aromatic amines.
SECTION–II :  Synthesis and biological evaluation of 4-Arylaminomethyl
     -3-β-pyridyl-1,N-phenylpyrazoles
Type  (XIII)      R=Aryl












The compounds of type (XIII) have been prepared by the reaction of compounds
of type (XII) with an. NaBH4.
PART-X   : STUDIES ON THIAZOLIDINONES
Compounds bearing thiazolidinone moiety are endowed with a variety of biological
activities such as antimicrobial, CNS depressant, antitubercular, sedative, anticonvulsant
etc. With a view to supplement these valid observations it was contemplated to synthesise
some 4-thiazolidinone derivative which have been described in following sections.
SECTION-I     :  Synthesis   and   biological    evaluation   of   2-Arylimino-5(H)-
                          4-thiazolidinones
The thiazolidinones of type (XIV) have been prepared by the action
monochloroacetic acid and sodium acetate in glacial acetic acid on thiourea derivatives
of different aromatic amine.
SECTION-II   :  Synthesis   and   biological   evaluation   of  2-Arylimino-5-(1’,N-
      phenyl-3’-β-pyridyl-pyrazol-4’-yl-methino)-4-thiazolidinones
Type  (XV)     R=Aryl














The thiazolidinones of type (XV) have been prepared by condensation of 1,N-
phenyl-3-β-pyridyl-4-formyl pyrazole moiety with different type (XIV) in glacial acetic
acid.
The constitution of newly synthesised compounds have been characterized using
elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography.
In Vitro study on multiple biological activities:
(1) All the compounds have been evaluated for their antibacterial activity towards
Gram positive and Gram negative bacterial strain and antifungal activity towards
Aspergillus Niger at a concentration of 40 ì g. The biological activity of the
synthesized compounds has been compared with standard drugs.
(2) Selected compounds have been evaluated for their in vitro biological assay like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37RV
at a concentration of 6.25 ì g/ml using Rifampin as standard drug, which have







Heterocyclic chemistry has seen unparalled progress owing to their wide natural
occurance, specific chemical reactivity and broad spectrum utility.
The variety of heterocyclic compounds is enormous, their chemistry is complex
and synthesizing them requires great skill. Among large number of heterocycles found in
nature, nitrogen hetero cycles are the most abundant than those containing oxygen or
sulfur owing to their wide distribution in nucleic acid instance and involvement in almost
every physiological process of plants and animals.
Most of the alkaloids which are nitrogenous bases occuring in plants and many
antibiotics including penicillin and streptomycin have also heterocyclic ring system. Many
natural pigments such as indigo, haemoglobin and anthocyanin are heterocycles. Most
of the sugars are their derivatives including Vitamin C for intance, exist largely in the
form of five membered. Vitamin B6 (Pyridoxine) is a derivative of pyrimidine essential in
aminoacid metabolism.Important drugs, poisons and medicines (both natural and
synthetic) such as sulphathiazole, pyrenthrin, rotenmone, strychnine, reserpine, certain
of the antihistaminics, the ergot alkaloids caeffine, cocaine, barbiturates, etc. are
heterocyclic compounds.
Heterocyclic compounds have great biological significance because :
1.    They have a specific chemical reactivity.
2.    They resemble essential metabolism and can also provide false synthons in
       biosynthetic process.
3.    They fit receptors and block their normal working.
4.    They provide convenient building blockers to which biologically active
       substituents can be attached.
The interesting biological activities of heterocycles have stimulated considerable
research work in recent years including to the synthetic utility.
13
Heterocyclic compounds can be synthesised by cyclisation reactions
(accompanied by elemination of small molecules), addition reactions (adduct formation),
ring transformation reactions or replacement involving groups. Formation of heterocycle
from acyclic compounds alters the reactivity. Piperidine is reactive than ethyl propylamine
due to the reduction in steric incumbrance of the nitrogen lone pair.
AIMS AND OBJECTIVES
In the pharmaceutical field, there is a need for new and novel chemical inhibitors
of biological functions. Our efforts are focused on the introduction of chemical diversity
in the molecular frame work in order to synthesising pharmacologically interesting
heterocyclic compounds of widely different composition.
During the course of research work looking to the applications of heterocyclic
compounds, several entities have been designed, generated and characterised using
spectral studies. The aims and objectives of the work carried out are as under.
1. To synthesise pharmacologically active entities like pyrazolines, oxopyrimidine,
thiopyrimidine, cyanopyran barbitones, aminopyrimidine, cyanopyridine, and
thiosemicarbazones, acetonitrile, azomethine and thiazolidinone bearing 1,N-
Phenyl-3-â-pyridyl pyrazole nucleus.
2. To characterise these products for structural elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
3. To check the purity of all compounds using thin layer chromatography.
4. To evaluate these new products for better drug potential against different
strains of bacteria, fungi and for antitubercular activity.
The research work is presented as studies on [A] Chalcones and [B]
Pyrazoles.
14
In a programmed research directed towards the construction of therapeutically
active new heterocycles bearing 1,N-Phenyl-3-â-pyridyl pyrazole nucleus has been
investigated in following parts.
[A]   STUDIES ON CHALCONES
PART - I : STUDIES ON PYRAZOLINES
PART - II : STUDIES ON PYRIMIDINES
PART - III : STUDIES ON CYANOPYRANS
PART - IV : STUDIES ON BARBITONES
PART - V : STUDIES ON AMINOPYRIMIDINES
PART - VI : STUDIES ON CYANOPYRIDINES
PART - VII : STUDIES ON THIOSEMICARBAZONES
[B]   STUDIES ON PYRAZOLES
PART - VIII : STUDIES ON α-ARYLAMINONITRILES
PART - IX : STUDIES ON N-ARYL-1,N-PHENYL -3-â-PYRIDYL-PYRAZOL-
  4-YL-AZOMETHINES
PART - X : STUDIES ON THIAZOLIDINONES





The chemistry of chalcones have generated intensive scientific studies throughout
the world, specially interesting for there their biological and industrial applications.
Chalcones are coloured compounds because of the presence of the chromophore and
auxochromes. They are known as benzalacetophenones or benzylidene acetophenones.
Kostanecki and Tambor1 gave the name Chalcone.
Chalcones are characterized by their possession of a structure in which two
aromatic rings A and B are linked by an aliphatic three carbon chain.
(I)
The alternative names given to chalcones are phenyl styryl ketones,
beanzalacetophenone, β-phenyl acrylphenone, γ-oxo-α,γ-diphenyl-α-propylene and α-
phenyl-β-benzoethylene.
SYNTHETIC ASPECT :
A considerable variety of methods are available in literature for the synthesis of
chalcones. The most convenient method is the one, that involves the  Claisen-Schimidt
condensation of equimolar quantities of an aryl methyl ketones with arylaldehyde in
presence of alcoholic alkali.2
Several condensing agents used are alkali of different strength3,4 hydrochloric
acid,5,6 phosphorous oxychloride,7 piperidine,8 anhydrous aluminium chloride,9 boron
trifluoride,10 aqueous solution of borax,11 amino acids,12 perchloric acid13 etc.
MECHANISM :
Chalcone formation proceeds through Aldol type condensation and the process





The intermediate Aldol type products formed readily undergoes dehydration even
under mild condition, particularly when R and R’ are aryl groups.
REACTIVITY OF CHALCONES :
The chalcones have been found to be useful for the synthesis of variety of
heterocyclic compounds are as under.
(a) Chalcones with monoethanolamine in ethanol gives 1,4-oxazipines.15
(b) Chalcones with 2-amino thiophenol in acetic acid produces 1,5-
thiazepines.16
(c) Chalcones on reaction with semicarbazide hydrochloride in ethanol affords
1-carboxamide pyrazolines.17
(d) Chalcones on reaction with 2-aminopyridine in glacial acetic acid affords
pyridopyrimidines.18
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(f) Cyanopyridone20 derivatives can be prepared by the condensation of
chalcone with ethyl cyanoacetate.
(g) Chalcones on reaction with barbituric acid gave barbitone21 derivatives.
(h) Chalcone gives imine derivatives with amine in presence of sulfuric acid as
catalyst.22
(i) Pyrazolines23 and its derivatives can be prepared by the condensation of
chalcones with hydrazine hydrate and acetic acid.
(j) Chalcones on condensation with malononitrile and ammonium acetate
yields 2-amino-3-cyano pyridines.24
(k) Isoxazoles25 can be prepared by the treatment of chalcones with
hydroxylamine hydrochloride and sodium acetate.
(l) Chalcones on condensation with malononitrile in pyridine forms 2-amino-
3-cyano-pyrans.26
(m) Chalcones on treatment with urea in presence of alkali  affords 2-
oxopyrimidines.27
(n) Chalcones on reaction with thiourea in presence of alkali/acid yields
2-thienopyrimidines.28
(o) Chalcones on treatment with guanidine hydrochloride in presence of
alkali affords 2-amino pyrimidines.29
(p) Chalcones react with P2S5 yielded 2-isothiazolidines.30
(q) Chalcones react with sodium nitrile in presence of glacial acetic acid in
ethanol produces 2-1H-pyrimidines.31
THERAPEUTIC INTEREST :
Chalcones are potential biocides, some naturally occurring antibiotics and amino
chalcones probably own their biological activity due to the presence of  α,β-unsaturated















Recently Ni Liming et. al.50 have synthesized chalcones and screened for their
antiinflammatory and cardiovascular activity. Kumar Srinivas et. al.51 have synthesized
chalcones as a antitumor agent. Ko Horng-Huey et. al.52 have prepared chalcones as
antiinflammatory agent. Nakahara Kazuhiko et. al.53 have synthesized chalcones as
carcinogen inhibitors. Antitubercular agents of chalcone derivatives have been prepared
by Lin Yuh-Meei et. al.54
Ezico et. al.55 have demonstrated that chalcone possess a valuable
antiproliferation activity both on sensitive cancereous cell and on cell which are resistant
to common chemotherapeutic drugs. Some of the chalcones have been  patented for
their use for treatment of glucoma56 and showed antifungal57,58 aldose reductase
inhibitors,59 anticancer60 and antimicrobial61,62 activities.
Das B. P. et. al.63 have found that chalcones possesses larvicidal properties.
Kim Min-Young et. al.64 have synthesized chalcones and tested for their matrix
metalloproteinase inhibitor activity. Satyanarayana M. et. al.65 have synthesized
chalcone derivatives as antihyperglycemic activity(II).
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Moreover, synthesis and antibacterial activity of substituted chalcone derivatives
have been reported by Modi et. al.66 and Attia A.67 V. Mudalir et. al.68 have prepared
phenoxychalcones and observed their insecticidal activity,  Kammei et. al.69 have
synthesized chalone derivatives having antitumor activity. De Vincenzo et. al.70 and Han
et. al.71 have reported chalcone derivatives for their antiinflammatory activity.
Aldose reductase inhibitor activity of chalcone derivatives have been reported
by Okuyama et. al.72 They are also associated with antitumor and antifungal activity as
reported by A. Tsotitns and coworkers.73 Antifeedant activity of chalcones have been
observed by Sharma and Sreenivasulu.74
Liu Mei et. al.75 have prepared antimalarial chalcones. Opletalova Veronika et.
al.76 have synthesized chalcones and screened as cardiovascular agents. Moreover, it
has been found that chalcone derivatives possesses nitric oxide inhibitor,77,78 anti
HIV79,80 and antiproliferative81,82 activities. Meng C. Q. et. al.83 discovered



















Moreover, Khatib S. et. al.84 synthesized some novel chalcones as potent
tyrosinase inhibitors(IV). Ko H. H. et. al.85 have prepared some new chalcones for
potent inhibition of platelet aggregation. Ziegler H. L. et. al.86 reported some  chalcones
as antiparasitic. Go M. L. et. al.87 have described the synthesis and biological activities
of chalcones as antiplasmodial. Xue C. X. et. al.88 synthesized  chalcones as antimalarial
agents. Fu Y. et. al.89 have synthesized Licochalcone-A.
Furthermore, Alcaraz M. J. et. al.90 have described the role of nuclear  factor
kappaB and heme oxygenase-1 in the action of an anti-inflammatory chalcone derivative
in RAW 264.7 cells. Nerya O. et. al.91 have prepared some new chalcones as potent
tyrosinase inhibitors.
Sabzevari O. et. al.92 have constructed some new chalcone derivatives as
Molecular cytotoxic mechanisms of anticancer hydroxychalcones(V).
Recently, Ban H. S. et. al.93 have synthesized some novel chalcones as inhibition
of lipopolysaccharide-induced expression of inducible nitric oxide synthase and tumor
necrosis factor-alpha by 2'-hydroxychalcone derivatives in RAW 264.7 cells. Hollosy
F. et. al.94 have prepared some new chalcones as Plant-derived protein tyrosine kinase













These valid observation led us to explore chalcone chemistry by synthesizing
several derivatives like pyrazolines, oxopyrimidines, thiopyrimidines, cyanopyrans,
barbitones, aminopyrimidines, cyanopyridine and thiosemicarbazones bearing different
heterocyclic ring systems for medicinal value, in order to achieving better therapeutic
agents, this study described as under.





Amongst nitrogen containing five membered heterocycles, pyrazolines have
proved to be the most useful framework for biological activities, pyrazolines have
attracted attention of medicinal chemists for both with regard to heterocyclic chemistry
and the pharmacological activities associated with them. In 1967 Jacobe, reviewed the
chemistry of pyrazolines, which have been studied extensively for their biodyndmic
behaviour98 and industrial applications99.
SYNTHETIC ASPECT :
Different methods for the preparation of 2-pyrazoline derivatives documented in
literature are as follows.
1. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones with
hydrazine hydrate100.
2. 2-pyrazolines can also be prepared by the condensation of chalcone dibromide
with hydrazines101.
3. 2-pyrazolines can be synthesised by the cycloaddition of diazomethane to
substituted chalcones102.
4. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile and the
N-aryl maleimides yields the corresponding pyrazolines103.
5. Epoxidation of chalcones have epoxy ketones which reacted with hydrazine and
phenyl hydrazine to givepyrazolines104.
Further more, B. Gyassi et. al.105 investigated the one pot synthesis of some
pyrazolines in dry media under microwave irradiation.  S. Paul et. al.106and Dandia














The following mechanism seems to be operable for the condensation of chalcones
with hydrazine hydrate.108









( i ) proton transfer



















Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl
system forms species (II), in which the -ve charge is mainly accomodated by the
electronegative oxygen atom.
Proton transfer from the nitrogen to -ve oxygen produces an intermediate enol
which simultaneously ketonises to ketoamine (III). Another intramolecular nucleophilic
attack by the primary amino group of ketoamine on its carbonyl carbon followed by
proton transfer from nitrogen to oxygen leads ultimately to carbonyl amine (IV). The
later with a hydroxy group and amino group on the same carbon lose water molecule to
yield the pyrazolines.
THERAPEUTIC IMPORTANCE








 6.  Herbicidal115
 7.  Hypoglycemic116
 8.  Insecticidal1117









S. S. Sonarc et. al.128 have synthesised-3-(2-acetoxy-4-methoxyphenyl)-5-
(substituted phenyl)-pyrazolines and tested their antimicrobial activity. H. H.Parekh129
et. al. have also synthesised some new pyrazolines as an antimicrobial agent. G. N.
Mishirika et. al.130 have also prepared 2-pyrazolines of salicyclic acid (II) possessing
antimicrobial properties.
Tunfawy, Atif and co-workers131 have patented 3-methyl-4'-(substituted
phenylazo)-pyrazol-5-ones as antibacterial agents.
Moreover F. Manna and co-worker132 have described 1-acetyl-5-(2'-
bromophenyl)-4,5-dihydro-3-(2'-hydroxyphenyl)-1H-pyrazolines and its derivatives
which acts as potent antiinflammatory, analgesic and antipyratic agents. Udupi R. H.
and Bhatt A. R.133 have reported the synthesis and biological activity of Mannich bases
of certain 1,2-pyrazolines. Nugent Richard134 investigated pyrazolines bis phosphonate
ester as novel antiinflammatory and antiarthritic agent.
Fuche Rainer et. al.135 have prepared some new 1H-pyrazoline derivatives and
reported them as pesticides. Furthermore, Tsubai et. al.136 have synthesised some new
(phenylcarbamoyl) pyrazolines as an insecticides and at 40% concentration shows 100%
mortality of spodopetra litura larve after seven drops.
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Moreover, T. M. Stivensen et. al.137have also investigated N-substituted
pyrazoline type insecticides. Tanka Katsohori138 have patented pyrazoline derivatives
as herbicides and Johannes et. al.139 as insecticides. Moritaz Z. and Hadol140 to
investigated a semi emperial molecular orbital study on the reaction of aminopyrazolinyl
azodye with singlet molecular oxygen.
Shivnanda M. K. and co-workers141 have prepared substituted pyrazolines and
reported their antibacterial activity. E. Palska et.  al.142 have prepared 3,5- diphenyl-
2-pyrazolines (I) and cited their antidepressant activity.
B. Shivrama et al.143,144 have synthesised pyrazolines as antibacterial agents.
Hiremath S. P. et. al.145 have synthesised pyrazolines as analgesics antiinflammatory
and antimicrobial agents. Malhotra V. et. al.146 have synthesised new pyrazolines as a
cardiovascular agents (II).
Almstead J. et. al.147 have prepared pyrazolines as vascularization agents. Guniz
Kuchkguzel et. al.148 have synthesised pyrazolines as a antimicrobial and anticonvalsant
agents. Gulhan T. Z. and co-workers149 have prepared pyrazolines as a hypotensive
agent. Shulabh Sharma et. al.150 have synthesised pyrazolines and tested their
antiinflammatory activity (III).
Ashok Kumar et.  al.151 have synthesised pyrazolines as anticonvulsant agents




R1 =H, Cl, Br, Me, MeO
R2 = H, Cl






























CONTRIBUTION FROM OUR LABORATORY
Parekh et. al.153 have prepared 1-Acetyl-5-aryl-3-[3,-(3,4-dihydro-2-methyl-
4-one-3-quinozalinyl)-phenyl]-2-pyrazolines which possess antimicrobial activity. Several
pyrazolines bearing thymol moiety were evaluated for their ability as potent antimicrobial
by Hansa Parekh et. al.154 Parekh and co-workers155 have prepared pyrazolines from
arsanilic acid for their antimicrobial activity. Parekh et. al.156,157 have synthesised and
reported the antimicrobial activity of pyrazolines.
Parikh et. al.158 have synthesised some antimicrobial pyrazolines. Parekh et.
al.159 have synthesised phenyl pyrazolines bearing quinoline (V) moiety and described
their antimicrobial activity. Parikh et. al.160 have synthesised and tested the antimicrobial
activity of p-(2',5'-dibromo benzene sulphonamido)-phenyl-5-aryl-1H/acetyl/phenyl-2-
pyrazolines (VI).
Recently, A. R. Parikh and co-workers have synthesised newer pyrazolines 161-
166 with variety of biological activity.
In view of therapeutic activities shown by pyrazolines, it was contemplated to
synthesise some new pyrazolines in search of agents possessing higher biological activity
with least side effect have been described as under.














R = Aryl, R1 = COCH3, Ph
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SECTION-II    : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-
ARYL-3-(1’,N-PHENYL-3’-β-PYRIDYL-PYRAZOL-4’-
YL)-2-PROPEN-1-ONES




SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-β-
PYRIDYL-4-FORMYL PYRAZOLE
SECTION-I
Recently, much  interest has been focused on the synthesis and biodynamic
behaviour of pyrazole aldehyde and it is a good synthon for various heterocyclic rings.
With a view to obtaining compounds having better therapeutic activity, we have synthesised






The constitution of the synthesised product has been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectoscopy. The mass
spectra of (1,N-Phenyl-3-β-pyridyl-4-formyl pyrazole) give m/z = 249 (recorded on
























Alkane C-H str. (asym.) 2923 2975-2925 95
-CH3 C-H str. (sym.) 2850 2880-2850  ,,
C-H i.p.def. (asym.) 1429 1470-1435  ,,
C-H o.o.p. def. (sym.) 1371 1390-1370  ,,
Aromatic C-H  str. 3141 3090-3030 96
C=C str. 1502 1540-1480  ,,
C-H i.p. (def.) 1101 1125-1090  ,,
C-H o.o.p. (def) 1051 1070-1000  ,,
Pyrazole C=N str. 1598 1610-1590 96
moiety C-N str. 1217 1230-1020  ,,
Αldehyde C=O str. 1678 1700-1640 95
Type        Ref.
        Reported
Frequency in cm-1 Vibration
Mode
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBrDisc.)

























































1 7.40-7.45 2H multiplet Ar-Hc,f     -
2 7.50-7.53 2H doublet Ar-Hbb’ Jbb’=6.9
3 7.79-7.82 2H doublet Ar-Haa’ Jji=7.95
4 8.24-8.28 1H multiplet Ar-Hg     -
5 8.57 1H singlet Ar-Hd     -
6 8.69-8.71 1H multiplet Ar-Hh     -
7 9.13 1H singlet Ar-He     -




    (δppm)
 Relative No.
  of  protons
Multiplicity Inference    J Value
    In Hz
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)































m/z = 247 (m-2)
m/z = 77 (m-1)m/z = 133 (m-2)











SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-β-
PYRIDYL-4-FORMYL PYRAZOLE
[A] Synthesis of 3-Acetyl pyridine phenyl hydrazone
A mixture of phenylhydrazine (1.08 g, 0.01 M) and 3-acetylpyridine (1.2 g, 0.01
M) in absolute ethanol was refluxed in water bath for 12hrs. in the presence of  glacial
acetic acid (1 ml). The crude product was crystallised from absolute alcohol. Yield 85%;
m.p. 108oC; (Anal. calcd. for C13H13N3; Required: C, 73.91; H,6.20; N,19.89 %;
Found: C, 73.81; H, 6.11; N,19.78 %).
[B] Synthesis of 1-Phenyl-3-β-pyridyl-4-formyl  pyrazole
3-Acetyl pyridine phenyl hydrazone (0.844 g, 0.004 M) was added to Vilsmeier-
Haack reagent (prepared by dropwise addition of 1.2 ml POCl3 in ice cooled 10 ml
DMF) and refluxed for 5 hrs. The reaction mixture was poured on to crushed ice followed
by neutralization using sodium bicarbonate. Crude product was isolated and crystallized
from ethanol. Yield, 80%; m.p. 154oC; (Anal. calcd. for C15H11N3O; Required:
C,72.28; H,4.45; N,16.86 % Found : C,72.16 ; H,4.34; N,16.73%).
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1’,N-PHENYL-
3’-β-PYRIDYL-PYRAZOL-4’-YL)-2-PROPEN-1-ONES
With the biodynamic activities of chalcones and it is a good synthon for various
heterocyclic rings, the interest has been focussed on the synthesis of new chalcones.
With a view to obtained compounds having better therapeutic activity, we have synthesized
1-Aryl-3-(1'N-phenyl-3'-β-pyridyl-pyrazol-4’-yl)-2-propen-1-ones by the condensation
of 1N-phenyl-3-β-pyridyl-4-formyl pyrazole with various aromatic ketones in presence
of catalyst of alkali.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy. The mass
spectra of 1-(p-Bromophenyl)-3-(1’,N-phenyl-3'-β-pyridyl-pyrazol-4’-yl)-2-propen-














Type - (II) R = Aryl
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Reaction Scheme





























Alkane C-H str. (asym.) 2966 2975-2950 95
-CH3 C-H str. (sym.) 2877 2880-2860  ,,
C-H i.p.def. (asym.) 1436 1470-1435  ,,
C-H o.o.p. def. (sym.) 1384 1390-1370  ,,
Aromatic C-H  str. 3070 3090-3030 96
C=C str. 1502 1540-1480  ,,
C-H i.p. (def.) 1093 1125-1090  ,,
C-H o.o.p. (def) 1031 1070-1000  ,,
Pyrazole C=N str. 1596 1610-1590 96
moiety C-N str. 1215 1230-1020  ,,
α,β-unsaturated C=O str. 1660 1700-1640 95
ketone CH=CH str. 1502 1644-1618  ,,
C-H wag. 979 980-965  ,,
Halogen C-Cl str. 686 600-800  ,,
Type        Ref.
        Reported
Frequency in cm-1 Vibration
Mode






















































    (δppm)
 Relative No.
  of  protons
Multiplicity Inference    J Value
    In Hz
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)
 NMR SPECTRAL STUDIES OF  1-(p-CHLOROPHENYL)ARYL-3-[1' ,N-
 PHENYL-3'-β-PYRDIAYL-PYRAZOL- 4'-YL]-2PROPEN-1-ONE
1 7.31-7.36 1H doublet Vin.Hm Jml=15.6
2 7.41-7.47 4H multiplet Ar-Ha,a’,c,h     -
3 7.52-7.53 2H doublet Ar-Hdd’ Jdd’=7.52
4 7.79-7.81 2H doublet Ar-Hbb’ Jbb’=8.1
5 7.89-7.92 2H doublet Ar-Hee’ Jee’=8.6
6 7.87-7.92 1H doublet Vin.Hl Jlm=15.5
7 8.0-8.3 1H doublet Ar-Hj Jjk=7.93
8 8.39 1H singlet Ar-Hf     -
9 8.70-8.72 1H doublet Ar-Hk Jkj=6.00

































































m/z = 391 (m-2)
m/z = 289 (m-1)
N
N









m/z = 158 (m-2)
NH2
N
m/z = 136 (m-2)
CH2
N
























Gram positive bacteria : B. cocous and B. subtillus
Gram negative bacteria : Proteus vulgaris
Escherichia coli
Fungi : Aspergillus niger
Concentration : 40 mg
Solvent : Dimethyl formamide
Standard drug : Amoxycillin, Benzoylpenicillin,
Ciprofloxacin, Erythromycin, Greseofulvin.
The antimicrobial activity was compared with standard drugs viz. Amoxycillin,
Benzoylpenicillin, Ciprofloxacin, Erythromycin, and antifungal activity was compared
with viz Greseofulvin. The zone of inhibition measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular activity was carried out at Tubrerculosis Antimicrobial
Acquisition and Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium tuberculosis H37Rv
Concentrtion : 6.25 mg/ml.
Standard drug : Rifampin
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1’,N-PHENYL-
3’-β-PYRIDYL-PYRAZOL-4’-YL)-2-PROPEN-1-ONES
[A] Synthesis of 1,N-Phenyl-3-β-pyridyl-4-formyl  pyrazole
See part-I, Section -I(B).
[B] Synthesis of 1-(p-Tolyl)-3-(1',N-phenyl-3'-β-pyridyl-pyrazol-4’-yl)-2-
propen-1-one
To a well stirred solution of  1,N-Phenyl-3-β-pyridyl-4-formyl pyrazole  (2.49
g, 0.01 M), p-Methylacetophenone (1.2 g, 0.01 M) in ethanol  (25 ml) and 40% NaOH
was added till the solution was basic. The reaction mixture was stirred for 24 hrs. The
contents were poured on to crushed ice, acidified, filtered and crystallised from ethanol.
Yield 75%;  m.p. 128oC.(Anal calcd. for C24H19N3O Found: C, 71.99; H, 4.68; N,
10.42; Required : C, 72.09; H, 4.54; N, 10.51%).
TLC solvent system : Acetone : Benzene (1: 9).
Similarly other substituted chalcones have been prepared.  The physical data are
recorded in Table No. 1.
[C] Antimicrobial activity of 1-Aryl-3-(1’,N-phenyl-3’-β-pyridyl-
pyrazol-4’-yl)-2-propen-1-ones
All the products have been evaluated by antimicrobial activity as described under.
(a) Antimicrobial activity




The purified products were screened for their antibacterial activity. The nutrient
agar broth prepared by the usual method was inoculated aseptically with 0.5 ml of 24
hrs. old subcultures of B. cocous, B. subtillus, E. coli, P. vulgaris in separate conical
flasks at 40-50oC and mixed well by gentle shaking. About 25 ml content of the flast
were poured and evenly spread in a pertidish (13 cm in diameter) and allowed to set for
2 hrs. The cup (10 mm in diameter) were formed by the help of borar in agar medium
and filled with 0.04 ml (40 mg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also maintained
with 0.04 ml of DMF in a similar manner and the difference zones of inhibition of the
bacterial growth with that of solvent were measured in millimeter and are recorded in
graphical chart no.1.
(II) Antifungal activity
A. Niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on Sabouraud's agar slants. Sterilised Sabouraud's agar
medium was inoculated with 72 hrs. old 0.5 ml of suspension of fungal spores in a
separate flask. About 25 ml of the inculated medium was evenly spreaded in a petridish
and allowed to set for two hrs. The cups (10 mm in diameter) were punched. The plates
were incubated at 30oC for 48 hrs. After the completion of incubation period, the zones
of inhibition of growth in the form of diameter in mm was measured Along the test solution,
in each petridish one cup was filled up with solvent which acts as control. The zones of
inhibition are recorded in graphical chart no.1.
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(b) Antitubercular Activity
The antitubercular evaluation of the compounds was carried out at Tuberculosis
Antimicrobial Acquisition and Co-ordinating Facility (TAACF), U.S.A. Primary screening
of the compounds for antitubercular activity have been conducted at 6.25 mg/ml towards
Mycobacterium Tuberculosis H37Rv in BACTEC 12B medium using the BACTEC
460 radiometric system. The compounds demonstrating atleast > 90%. inhibition in the
primary screen have been retested at lower concentration towards Mycobacterium
Tuberculosis H37Rv  to determine the actual minimum inhibitory concentration (MIC)
in the BACTEC 460.
The antitubercular activity data have been compared with standard drug Rifampin
at 0.25 mg/ml concentration and it showed 98% inhibition. The data for % inhibition
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-ARYL-5-
(1',N-PHENYL-3'-β-PYRIDYL-PYRAZOL-4’-YL)-PYRAZOLINES
Looking to the interesting therapeutic activities of pyrazolines, it was considered
worthwhile to synthesise compounds bearing 1,N-Phenyl-3-β-pyridyl-4-formyl pyrazole
moiety linked to the pyrazoline of type- (III) which have been prepared by the action of
1-aryl-3-(1',N-phenyl-3'-β-pyridyl-pyrazol-4’-yl)-2-propen-1-ones   with phenyl














The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also. The mass spectra of 1,N-Phenyl-3-(p-tolyl)-5-(1',N-phenyl-3'-β-
pyridyl-pyrazol-4’-yl)-pyrazoline give m/z = 455 (recorded on Page No. 50). The
fragmentation is also explained (Page No. 51).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger  at a concentration of 40 mg/ml. The biological
activities of synthesised compounds were compared with standard drugs.
Type - (III) R = Aryl
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 Observed
Alkane C-H str. (asym.) 2923 2975-2920 95
-CH3 C-H str. (sym.) 2852 2880-2850  ,,
C-H i.p.def. (asym.) 1411 1470-1435  ,,
C-H o.o.p. def. (sym.) 1384 1390-1370  ,,
Aromatic C-H  str. 3078 3090-3030 96
C=C str. 1502 1540-1480  ,,
C-H i.p. (def.) 1097 1125-1090  ,,
C-H o.o.p. (def) 839 835-810  ,,
Pyrazole C=N str. 1600 1610-1590 96
moiety C-N str. 1222 1230-1020  ,,
Pyrazoline C-N str. 1097 1230-1020  ,,
C=N str. 1600 1650-1550  ,,
Halide C-Cl str. 756 600-800 95
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)












    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)



























1 2.4 3H        singlet Ar-CH3        -
2 3.00-3.09 1H        quartet CHB        -
3 3.45-3.54 1H        quartet CHA        -
4 5.08-5.18 1H         triplet CHX        -
5 7.18-7.20 2H        doublet Ar-CHa,a’       7.8
6 7.25-7.32 1H        doublet Ar-CHp       7.5
7 7.42-7.48 3H         multiplet Ar-CHf,d,q        -
8 7.55-7.57 4H         multiplet Ar-CHj,l,g,c        -
9 7.63 1H         triplet Ar-CHk        -
10 7.73-7.71 2H        doublet Ar-CHb,b’       8.1
11 7.79-7.82 1H         triplet Ar-CHe        -
12 8.05-8.09 3H         multiplet Ar-CHi,m,o        -
13 8.61-8.63 1H        doublet Ar-CHn       4.32



































































































m/z = 118 (m+2)
m/z = 261 (m+1)
m/z = 221
m/z = 246 (m+2)
m/z = 261 (m+2)
m/z = 376 (m+2)
m/z =350 (m+2)
m/z = 91 (m+2)
m/z = 379




SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-ARYL-5-
(1',N-PHENYL-3'-β-PYRIDYL-PYRAZOL-4’-YL)-PYRAZOLINES
[A] Synthesis of 1,N-Phenyl-3-β-pyridyl-4-formyl  pyrazole
See part-I, Section -I(B).
[B] Synthesis of 1-(p-Anisyl)-3-(1',N-phenyl-3'-β-pyridyl-pyrazol-4’-yl)-2-
propen-1-one
See Part-I, Section-II (B).
[C] Synthesis of 1,N-Phenyl-3-(p-anisyl)-5-(1',N-phenyl-3'-β-pyridyl-
pyrazol-4’-yl)-pyrazoline
To a mixture of 1-(p-Anisyl)-3-(1’,N-phenyl-3’-β-pyridyl-pyrazol-4’-yl)-2-
propen-1-one (3.81 g, 0.01M) in 25 ml of  absolute alcohol  add phenyl hydrazine
(1.08g, 0.01M) was added in the presence of basic catalyst like piperidine and refluxed
for 12 hrs. at 70oC. The reaction product was poured into ice. The product was isolated
and crystallised from ethanol Yield 57%, m.p. 232oC (C30H25N5O; Found : C, 79.04%;
H, 5.50%; N, 14.82%; Requires : C, 79.10%; H, 5.53%; N, 14.85%).
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 2.
[D] Antimicrobial activity of 1,N-Phenyl-3-aryl-5-(1',N-phenyl-3'-β-pyridyl-
pyrazol-4’-yl)-pyrazolines
All the products have been evaluated by antimicrobial activity as described  in
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Pyrimidine derivatives like uracil(I), thymine(II) and cytosin(III) occur widely in
nature showing remarkable pharmaceutical importance because of their diverse biological
activities. Several analoges of nucleic acids have been used as compounds that interfere with
the synthesis and fuctioning of nucleic acids, an  example is fluorouacil which has been used
in the cancer treatment.
















Pyrimdine ring carrying various substituents may be built up from two or three
aliphatic fragments of other synthesis which are complimentary rather than
alternative to it. Despite considerable localisation of π-electrons, at the nitrogen atom
of oxopyrimidine and the sulphur atom of thiopyrimidine, the ring system is still
sufficiently aromatic to possess substantial stability.
SYNTHETIC ASPECTS :-
Popular methods for the preparation of pyrimidine derivatives have been reported
by synthesis from a cyclic precursors, which have been described under the
following synthesis.
1. Tauki Aaruki and co-workers 167 have prepared oxopyrimidine derivatives by
treatment with urea in alcoholic KOH.
2. Hussain Ali Saleiman et. al.168 have prepared oxoyrimidine derivatives(IV) by
















3. By the condensation  of  â-keto ester with thiourea and aldehyde169-170.
4. Wang Jinjum171 have prepared some new benzo[c] pyrano[4,3-d] pyrimidine
derivatives(V).
MECHANISM :
The reaction proceeds through conjugated addition of thiourea or urea to
the α,β-unsaturated system. The bond formation take place between N-atom of
 thiourea or urea and C-atom of chalcone.
(V)
R = Ph, 4-ClC6H4,
      3-OCH3C6H4

























































In the first step migration of electron takes place due to the more electronegativity
of O-atom than C-atom. So carbon has positive charge while nitrogen atom looses proton
so it aquires negative charge, with simultaneous removal of water.
THERAPEUTIC IMPORTANCE
Pyrimidine derivatives have proven to be of great importance in exhibiting and




4.  Antiinflammatory and analgesic175-177
5.  Antineoplastic178,179
6.  Antiviral and antitumor180,181




J. Lewis187 have prepared oxo-pyrimidines and found to be active as bactericidal
and antiviral, H. Junek and co-workers188 have prepared pyrimidines (VI) which were
found to possess antiviral activity.
Baldev Kumar et. al.189 have prepared some new oxopyrimidine derivatives
(VII) and reported them as potent calcium channel blockers.  Abd. EL-Galil and M.
Abdulla190 have synthesised  some fused steroidal oxopyrimidine derivatives (VIII)























Erker T. et. al.191 have prepared thiopyrimidines which have been shown to
possess muscle relaxant activity. Breozowskii Z. 192 found thiopyrimidine as anti-HIV.
Nakatsuka M. et. al. 193 prepared thiopyrimidines active against inflammmation.
Abou EL-Fotooh et. al.194 prepared thiopyrimidine derivatives (IX) which showed
anticancer activity.
Pyrimidine derivatives have attracted us in view of their  great biological activity.
Taking this into considertion, the synthesis of some novel pyrimidines has been designed
which are described as under.




X = Cl, Br, I, 3,4-(OCH3)2














SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-(1’,N-
PHENYL-3'-â-PYRIDYL-PYRAZOL-4’-YL)-2,3-DIHYDROPYRIMIDINE-
2-THIONES
With a view to synthesising the compounds having better therapeutic activity the
pyrimidines of type (IV) have been prepared by the condensation of 1-Aryl-3-(1’,N-
phenyl-3’-â-pyridyl-pyrazol-4’-yl)-2-propen-1-one and thiourea  in presence of al. KOH
as catalyst as given  below.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectroscopy. The mass spectra of  6-(p-Tolyl)-4-(1’,N-phenyl-3'-
â-pyridyl-pyrazol-4’-yl)-2,3-dihydropyrimidine-2-thione give m/z = 421 (recorded on
Page No. 64). The fragmentation is also explained (Page No. 65).
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The biological
activities of the synthesized compounds were compared with standard drugs.
The synthesised compounds have been screened for their in vitro biological assay
like antitubercular activity towards a strain of Mycobacterium tuberculosis H37Rv at
concentration of 6.25 mg/ml using Rifampin as standard drug.


















Alkane C-H str. (asym.) 2924 2975-2920 95
-CH3 C-H str. (sym.) 2851 2880-2850  ,,
C-H i.p.def. (asym.) 1446 1470-1435  ,,
C-H o.o.p. def. (sym.) 1354 1390-1370  ,,
Aromatic C-H  str. 3053 3090-3030 96
C=C str. 1598 1540-1480  ,,
C-H i.p. (def.) 1172 1125-1090  ,,
C-H o.o.p. (def) 813 835-810  ,,
Pyrazole C=N str. 1573 1610-1590 95
moiety C-N str. 1226 1230-1020  ,,
Thio
pyrimidine C-N str. 1226 1230-1020  ,,
N-H str. 3382 3400-3250  ,,
C=S str. 1172 1200-1020  ,,
Halide C-Cl str. 758 600-800 96
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode





















































    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)
























1 2.35 3H singlet Ar-CH3        -
2 7.10-7.17 4H multiplet Ar-Ha,a’        -
Ar-Hb,b’        -
3 7.24-7.30 3H multiplet Ar-Hc,dd’        -
4 7.48-7.55 3H multiplet Ar-Hl,ee’        -
5 7.74-7.77 1H doublet Ar-Hh        7.86
6 7.99-8.01 1H doublet Ar-Hj        7.84
7 8.32 1H singlet Ar-Hf        -
8 8.47-8.48 1H doublet Ar-Hk        -
9 8.88 1H singlet Ar-Hg        -



















































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-(1’,N-PHENYL-
3'-â-PYRIDYL-PYRAZOL-4’-YL)-2,3-DIHYDROPYRIMIDINE-2-THIONES
[A] Synthesis of 1-Phenyl-3-â-pyridyl-4-formyl  pyrazole
See part-I, Section -I(B).
[B] Synthesis of 1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-2-
propen-1-one
See Part-I, Section-II (B).
[C] Synthesis of 6-(p-Tolyl)-4-(1’,N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-
2,3-dihydropyrimidine-2-thione
To a mixture of 1-(p-Tolyl)-3-(1’,N-phenyl-3’-â-pyridyl-pyrazol-4’-yl)-2-
propen-1-one (3.65 g, 0.01M) in 25 ml of  absolute alcohol  add al. KOH  and refluxed
for 12 hrs. at  70oC. The reaction product was poured into ice. The product was
isolated and crystallised from ethanol Yield 54%, m.p. 232oC (C25H21N5S; Found :
C, 71.14%; H, 4.52%; N, 16.59%; Requires :C, 71.23%; H, 4.54%; N, 16.61%;).
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 3.
[D] Antimicrobial activity of 6-Aryl-4-(1’,N-phenyl-3'-â-pyridyl-
pyrazol-4’-yl)-2,3-dihydropyrimidine-2-thiones
Antimicrobial testing was carried out as described in Part-I, Section-II (C).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.3.
Antitubercular  screening of the compounds of type(IV) were carried out by
TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-II





































































































































































































































































































































































































































































































































































































































































































































































   
   
























   
   






































   
   
  1
   
   
   
2
   
   
   
   
   
  3
   
   
   
4
   
   
 5

















   
   
   
   
   
   
   
   






















   
   
   
   
   
   
   
   














   
   
   
   
   





   
   
   
   
   
   
   

















   
   
   
   



















































































































































































   
   











Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute






























Rv >6.25 02 - "







Rv >6.25 33 - "






Rv >6.25 30 - "
RKP-72 295740 3-NO2-C6H4- Alamar H37Rv >6.25 16 - "































TABLE NO. 3a     :      PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
71
SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-(1’,N-PHENYL-
3'-â-PYRIDYL-PYRAZOL-4’-YL)-2,3-DIHYDROPYRIMIDINE-2-ONES
With a view to synthesising the compounds having better therapeutic
activity the pyrimidines of type (V) have been prepared by the condensation of 1-Aryl-
3-(1’,N-phenyl-3’-â-pyridyl-pyrazol-4’-yl)-2-propen-1-ones and  urea  in presence
of al. KOH as catalyst as given  below.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H  nuclear magnetic resonance spectroscopy and further
supported by mass spectroscopy. The mass spectra of  6-(p-Tolyl)-4-(1’,N-phenyl-3'-
â-pyridyl-pyrazol-4’-yl)-2,3-dihydropyrimidine-2-one give m/z = 407 (recorded on Page
No. 74). The fragmentation is also explained (Page No. 75).
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The biological
activities of the synthesized compounds were compared with standard drugs.
The synthesised compounds have been screened for their in vitro biological assay
like antitubercular activity towards a strain of Mycobacterium tuberculosis H37Rv at
concentration of 6.25 mg/ml using Rifampin as standard drug.


















Alkane C-H str. (asym.) 2920 2975-2920 95
-CH3 C-H str. (sym.) 2852 2880-2850  ,,
C-H i.p.def. (asym.) 1438 1470-1435  ,,
C-H o.o.p. def. (sym.) 1352 1390-1370  ,,
Aromatic C-H  str. 3055 3090-3030 96
C=C str. 1595 1540-1480  ,,
C-H i.p. (def.) 1093 1125-1090  ,,
C-H o.o.p. (def) 825 835-810  ,,
Pyrazole C=N str. 1595 1610-1590 95
moiety C-N str. 1213 1230-1020  ,,
Oxo
pyrimidine C-N str. 1213 1220-1020  ,,
N-H str. 3361 3400-3250  ,,
C=Ostr. 1676 1700-1640  ,,
Halide C-Cl str. 750 600-800 96
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode





























































    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)
PMR SPECTRAL STUDY OF  6-(p-ANISYL)-4-(1’,N-PHENYL-3'-â -PYRIDYL-
PYRAZOL-4’-YL)-2,3-DIHYDROPYRIMIDINE-2-ONE
1 3.85 3H singlet Ar-OCH3        -
2 7.42-7.45 2H doublet Ar-Ha,a’    Jaa’=7.8
3 7.45-7.48 2H doublet Ar-Hb,b’    Jbb’=6.9
4 7.51-7.56 3H multiplet Ar-Hc,dd’        -
5 7.79-7.82 2H doublet Ar-He,e’    Jee’=8.01
1H singlet Ar-Hl        -
6 7.99-8.09 1H multiplet Ar-Hh        -
7 8.25-8.27 1H multiplet Ar-Hj        -
8 8.57 1H singlet Ar-Hf        -
9 8.70-8.71 1H doublet Ar-Hk        -
10 9.13 1H singlet Ar-Hg        -


























































































m/z = 407 (m+2)
m/z = 135 (m+2)
m/z = 203 (m+3)
m/z = 145
m/z = 161
m/z = 145 (m-1)
m/z = 92
m/z = 105 (m+2)
m/z = 134 (m+1)











SYNTHESIS AND BIOLOGICAL EVALUATION OF 6 - ( p - T O LY L ) - 4 - ( 1 ’ , N -
PHENYL-3'-â-PYRIDYL-PYRAZOL-4’-YL)-2,3-DIHYDROPYRIMIDINE-2-ONE
[A] Synthesis of 1-Phenyl-3-â-pyridyl-4-formyl  pyrazole
See part-I, Section -I(B).
[B] Synthesis of 1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-2-
propen-1-one
See Part-I, Section-II (B).
[C] Synthesis of 6-(p-Tolyl)-4-(1’,N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-2,3-
dihydropyrimidine-2-one
To a mixture of 1-(p-Tolyl)-3-(1’,N-phenyl-3’-â-pyridyl-pyrazol-4’-yl)-2-propen-
1-one (3.65 g, 0.01M) in 25 ml of  absolute alcohol  add al. KOH  and refluxed for 12
hrs. at temp 70oC The reaction product was poured into ice. The product was isolated
and crystallised from ethanol Yield 54%, m.p. 232oC (C25H21N5O; Found : C, 74.01%;
H, 4.69%; N, 17.24%; Requires :C, 74.06%; H, 4.72%; N, 17.27%;).
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 4.
[D] Antimicrobial activity of 6-Aryl-4-(1’,N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-
2,3-dihydropyrimidine-2-ones
Antimicrobial testing was carried out as described in Part-I, Section-II (C). The
zone of inhibition of the test solutions are recorded in Graphical Chart No.4.
Antitubercular  screening of the compounds of type(V) were carried out by
TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-II (C)
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Rv >6.25 11 - "







Rv >6.25 54 - "






Rv >6.25 50 - "
RKP-82 295750 3-NO2-C6H4- Alamar H37Rv >6.25 15 - "





































The chemistry of pyran with different functional groups exhibit wide range of
applications in the field of pharmaceuticals, dyes, insecticides and sweet smelling
substances. Pyran ring system is also present in large number of natural coloured
compounds in Vitamin E, hemorrhagic compound in cloves, in fish poisions, in certain
alkaloids and other substances. Pyran is a doubly unsaturated six membered ring system
with a single oxygen as hetero atom. The two double bonds may be conjugated as α or
1,2-pyran or isolated as in γ or 1,4-pyran.
A degree of stabilisation of the pyran nucleus is achieved by substituting phenyl
group in the 2 or 4 and preferably also in the 6 position.
SYNTHETIC ASPECT
Various methods for the preparation of pyran derivatives have been cited in the
literature195-204.
1. Reaction between (A) with CH2(CN)2 led to the corresponding 2-amino-3-cyano-
 4H-pyrans (B)205.
MECHANISM :
The reaction of malononitrile with  α, β-unsaturated  system  leads to the





















Literature survey revealed that various pyrans have resulted in many potential







7. CNS active agent216
8. Cytotoxic217
9. Inhibitors of cell proliferation218





Moreover, Fathy F. Abdel-Latif et. al.224 have reported the synthesis of 2-amino-
3-cyanopyran derivatives and studied their biological activity. Piao Minz, Zhu et. al.225
have prepared biologically active 2-amino pyran derivatives. Sharanin Y. U. A. et. al.226





































Zwaagstra Mariel et. al.227 have newly synthesised pyran derivatives and tested
for antiashamatic activity. Boyer Frederick et. al.228 have prepared some new-2-amino-
3-cyano-4H-pyran and reported anti HIV agent and antiviral activity.  Some of the pyran
derivatives have been patented for their use as antihypertensive229, antiestogens230,
antagonist231,232, antitumor233 and antiviral234 activities. Synthesis and biological
activity of pyran ring system have been reported by O’Brien  et. al.235.
Synthesis and anticancer activity of pyran (V) containing flourine have been
reported by Mohamed S. Abd et. al.236 4H-pyran of type (VI) were prepared to enhance




























El-Subbagh and co-worker237 have synthesised cyanopyran derivatives and
showed their antiviral activity. Corbou Romuld et. al.238 have synthesised cyanopyran
derivatives (VII) which have significant pharmacological activity.
CONTRIBUTION FROM OUR LABORATORY
Parikh A. R. et. al.239 have synthesised cyanopyrans bearing 2-chloro-6-
bromoquinoline nucleus as a potential antimicrobial and anticancer agents. With a view
to get better therapeutic agent, it was contemplated to synthesise pyran derivatives to
enhance the overall activity of resulting compounds which have been described as under.













SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-6-ARYL-3-
CYANO-4-[1’,N-PHENYL-3’-â-PYRIDYL-PYRAZOL-4’-YL]-4H-PYRANS
In the past years, considerable evidence has been accumulated to demonstrate
the efficiency of cyanopyrans. To further assess the potential of such a class of compounds
cyanopyran derivatives of type (VI) have been synthesised by condensation of
malononitrile  with 1-Aryl-3-(1',N-phenyl-3'-β-pyridyl- pyrazol-4’-yl)-2-propen-1-
ones.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.The mass spectra of 2-Amino-6-(p-anisyl)-3-cyano-4-[1’,N-phenyl-
3’-â-pyridyl-pyrazol-4’-yl]-4H-pyran give m/z = 447 (recorded on Page No. 88). The
fragmentation is also explained (Page No. 89).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological
activity of synthesised compounds were compared with standard drugs.
























Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2916 2995–2920 95
 –CH
3
C – H str. (sym.) 2854 2880–2850 "
C – H i.p. (def.) 1448 1470–1435 "
C – H o.o.p. (def.) 1380 1385–1330 "
Aromatic C – H str. 3060 3080–3010 96
C – H i.p. (def.) 1064 1110–1000 "
C – H o.o.p (def.) 837 835–810 "
Pyrazole C = N str. 1595 1650–1600 96
moiety C – N str. 1232 1350–1200 "
Ether C- O-C str. (sym.) 1232 1275-1200 "
Ar-O-CH3 C- O-C str. (sym.) 1064 1075-1020 "
                                      Overlapped
Pyran C = C  str. 1595 1650-1520 95
                                      Overlapped
N- H str. 3355 1075–1020 "
N- H def. 1595 1075–1020 "
C≡N str. 2216 2240-2210 "
87





    (δppm)
 Relative No.
  of  protons
Multiplicity Inference
    Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
   J Value
    In Hz
1 3.85 3H singlet Ar-OCH3     -
2 4.18 1H singlet Ar-Hl     -
3 6.93-6.96 2H doublet Ar-Hbb’ Jbb’=8.8
4 7.35-7.42 2H multiplet Ar-Hh,m     -
5 7.51-7.56 3H multiplet Ar-Hc,d,d’     -
6 7.84-7.87 4H doublet Ar-Haa’ Jaa’=7.9
doublet Ar-Hee’ Jee’=8.0
7 7.92-7.97 1H d,d Ar-Hj Jjh=9.4
Jjk’=9.7
8 8.52 1H singlet Ar-Hf     -
9 8.61-8.63 1H doublet Ar-Hk Jij=5.6
































































































m/z = 213 (m+2)
m/z = 228 (m+2)
m/z = 145 (m+2)
m/z = 402 (m+1)
m/z = 432 (m+1)
m/z = 352 (m+2)
m/z = 414 (m+2)


















SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-6-ARYL-3-
CYANO-4-[1’,N-PHENYL-3’-â-PYRIDYL-PYRAZOL-4’-YL]-4H-PYRANS
[A] Synthesis of 1,N-Phenyl-3-â-pyridyl-4-formyl pyrazole
See Part-I, Section-I (B).
[B] Synthesis of 1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-
2-propen-1-one
See Part-I, Section-II (B).
[C] Synthesis of 2-Amino-6-(p-tolyl)-3-cyano-4-[1’,N-phenyl-3'-â-pyridyl-
1H-pyrazol-4’-yl]-4H-pyran
A mixture of 1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-2-propen-
1-one (3.65 g, 0.01 M), malononitrile (0.66 g, 0.01 M) and 2 ml pyridine  dissolved in
absoulte alcohol was refluxed for 8 hrs. in water bath at 70oC. The reaction product
was poured into ice, crude product was isolated, crystallised from ethanol. Yield 47%,
m.p. 196oC (C27H21N5O ; Found : C, 75.10%; H, 4.86%; N, 16.20%; Requires : C,
75.16%; H, 4.91%; N, 16.23%).
Similarly other cyanopyrans have been obtained. The physical data are recorded
in Table No. 5.
[D] Antimicrobial activity of 2-Amino-6-aryl-3-cyano-4-[1’,N-phenyl-3'-
â-pyridyl-1H-pyrazol-4’-yl]-4H-pyrans
Antimicrobial testing was carried out as described in Part-I, Section-II (C). The
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Barbituric acid derivatives have gained prominance because of their potential
pharmaceutical values. Many barbituric acid derivatives play vital role in many
physiological action. Most important is the effect of barbiturates on the central nervous
system. There are more than 40 synthetic drugs bearing barbituricacid, moiety in use
recently. They possess diverse type of biological properties including hypnotic, sedatives,
anticonvulsant, cardiovascular etc. The first member of hypnotic drugs series was barbital
(I).
Barbituric acid ring system has been found in many natural products like alkaloids,
which includes Xanthine (II) and Theophyline (III) are constituents of tea leaves.
Theobromine is found in cocoa beans.
SYNTHETIC ASPECT
Different methods are used for the preparation of barbitones in literature240,241.
1. Cao-Yun Weu et. al.242 have prepared barbituric acid derivatives by the
action of different aldehydes with barbituric acid in basic media.













































3. Ogus Funda et. al.244 have synthesised barbiturates by the reaction between
























Barbituric acid derivatives demonstrate a very broad spectrum of biological
activity, because of their structural relationship with nucleic acids, viz. uracil, thymine
and cytosine. Perhaps barbituric acid derivatives are most widely used pyrimidines
in medicinal chemistry.
Phenobarbitone (IV) possess sedative and hypnotic activities, thiopentone (V)
is a useful local anaesthetic while Eterobarb (VI) is an anticonvulsant drug.
Carbubarb245 is a barbituric acid derivative, which is used as a veternary
anaesthetics. Some isoxazole pyrimidine derivatives have been studied because of
their potential as as pesticidal246,247 activity. Some barbiturates showing
cardiovascular248-250 and analgesic and antiinflammatory activities251 have been
reported.
Ulf Wellmar et. al.252 have synthesised some uracil derivatives and screened
for antiviral activity253,254. Raymond et. al.255 investigated some barbiturates (VII),
showing anticancer activity while Mahmoud et. al.256 reported their antimicrobial activity.
96
Some isoxazolo pyrimidine derivatives have been extensively studied and
reported as antagonist257 and antitumor258 agents. Agricultural activity of 5-
(3-benzylthiazolidin-2-ylidene)-1,3-dimethyl hexahydro pyrimidine-2,4,6-trione
was reported by Wolf-Gang et. al.259 Harbicidal and insecticidal activity of
barbiturates was documented by Andre Roland and co-workers260. Omar M.
T.261 have showed barbitone derivatives demonstrating antimicrobial activity.
Sakai and co-workers262 has synthesised some new barbitones which are
assessed for bone and cartilage diseases. R. T. Pardasani and co-workers263
have described some new isatyl idene barbi tones (VIII)  and tested their
antibacterial activity.
Vital contribution of barbituric acid ring system to the medicinal chemistry as an
active constituent of hypnotics and sedatives made chemists to explore for its other
derivatives as therapeutic agents. Accordingly several derivatives of barbituric acid have



















R1, R2 = H
R1 = OCH3
 R2 = H
R’ = Alkyl / X / H
SECTION - I :SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-
       [1-ARYL-3-(1’,N-PHENYL-3’-â-PYRIDYL-1,H-PYRAZOL-
      4’-YL)-PROP-2-ENYLIDENE]PYRIMIDINE-2,4,6
      (1H,3H,5H)-TRIONES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-[1-ARYL-3-(1’,N-PHENYL-
3’-â-PYRIDYL-1,H-PYRAZOL-4’-YL)-PROP-2-ENYLIDENE]PYRIMIDINE-
2,4,6(1H,3H,5H)-TRIONES
Barbiturates are known to play an important role in medicinal chemistry
because of their effect on central nervous system. The first member of hypnotic
drugs series was barbital. Considering this background, some new barbituric
acid derivatives of type (VII) were prepared by the condensation of compounds
of type (II) with barbituric acid in glacial acetic acid.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.The mass spectra of 5-[1-(p-Anisyl)-3-(1’,N-phenyl-3’-â-pyridyl-
1,H-pyrazol-4’-yl)-prop-2-enylidene]pyrimidine-2,4,6(1H,3H,5H)-trione give m/z = 491
(recorded on Page No. 100). The fragmentation is also explained (Page No.101).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological















Type - (VII)   R = Aryl
98
IR SPECTRAL STUDY OF  5-[1-(p-ANISYL)-3-(1’,N-PHENYL-3’-â-PYRIDYL-1,H-
PYRAZOL-4’-YL)-PROP-2-ENYLIDENE]PYRIMIDINE-2,4,6(1H,3H,5H)-TRIONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2953 2995–2920 95
 –CH
3
C – H str. (sym.) 2850 2880–2850 "
C – H i.p. (def.) 1425 1470–1435 "
C – H o.o.p. (def.) 1355 1385–1330 "
Aromatic C – H str. 3055 3080–3010 96
C =C str. 1500 1540-1480
C – H i.p. (def.) 1016 1110–1000 "
C – H o.o.p (def.) 829 835–810 "
Pyrazole C = N str. 1598 1650–1600 96
moiety C = C str. 1525 1585–1480 "
C – N str. 1222 1350–1200 "
Barbitone N- H str. 3209 3400-3200













    (δppm)
 Relative No.
  of  protons
Multiplicity Inference
1 7.34-7.39 1H doublet Vin.Hm Jml=15.5
2 7.51-7.57 3H multiplet Ar-Hh,aa’     -
3 7.63-7.67 3H multiplet Ar-Hc,dd’     -
4 7.79-7.81 2H doublet Ar-Hbb’ Jbb’=7.5
5 7.81-7.85 1H doublet Vin.Hl Jlm=14.9
6 7.81-7.84 2H doublet Ar-Hee’ Jee’=8.3
7 8.23-8.25 1H doublet Ar-Hf     -
8 8.41 1H singlet Ar-Hk     -
9 8.71-8.73 1H multiplet Ar-Hg     -
10 9.08 1H singlet Ar-Hj Jjk=7.60
   J Value
    In Hz

















































































































m/z = 367 (m+2)
m/z = 414
m/z = 385
m/z = 214 (m-1)
m/z = 160 (m+2)
m/z = 137 (m+1)
m/z = 290



















SYNTHESIS AND BIOLOGICAL EVALUATION OF  5-[1-ARYL-3-(1’,N-
P H E N Y L - 3 ’ - â - P Y R I D Y L - 1 , H - P Y R A Z O L - 4 ’ - Y L ) - P R O P - 2 -
ENYLIDENE]PYRIMIDINE-2,4,6(1H,3H,5H)-TRIONES
[A] Synthesis of 1,N-Phenyl-3-â-pyridyl-4-formyl pyrazole
See Part-I, Section-I (B).
[B] Synthesis of 1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-
2-propene-1-one
See Part-I, Section-II (B).
[C] Synthesis of 5-[1-(p-Tolyl)-3-(1’,N-phenyl-3'-â-pyridyl-1,H-pyrazol-4’-yl)-
prop-2-enylidene]pyrimidine-2,4,6(1H,3H,5H)-trione
A mixture of 1-(p-Tolyl)-3-(1'-N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-2-propene-
1-one (3.65 g, 0.01 M) in ethanol & barbituric acid (1.28 g, 0.01 M)in glacial acetic
acid was refluxed for 8 hrs. on oil bath. The reaction product was poured into ice, crude
product was isolated, crystallised from ethanol. Yield 70%, m.p. 196oC (C28H21N5O3
; Found : C, 70.68%; H, 4.41%; N, 14.70%; Requires : C, 70.73%; H, 4.45%; N,
14.73%).
Similarly other cyanopyrans have been obtained. The physical data are recorded
in Table No. 6.
[D] Antimicrobial activity of 5-[1-Aryl-3-(1’,N-phenyl-3'-â -pyridyl-1,H-
pyrazol-4’-yl)-prop-2-enylidene]pyrimidine-2,4,6(1H,3H,5H)-triones
Antimicrobial testing was carried out as described in Part-I, Section-II (C). The
 zone of inhibition of the test solutions are recorded in Graphical Chart  No.6.
Antitubercular  screening of the compounds of type(V) were carried out by
TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-II (C)
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TABLE NO. 6a    :       PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute






























Rv >6.25 0 - "







Rv >6.25 41 - "






Rv >6.25 0 - "
RKP-40 295708 3-NO2-C6H4- Alamar H37Rv >6.25 6 - "




































2-Aminopyrimidine is the most important member of all the diazine as this ring
system occurs widely in living organisms. Pyrimidine was first isolated by Gabriel and
Colman in 1899. 2-Amino pyrimidine and its derivatives represent one of  the most
active class of compounds possessing a wide spectrum of biological activities.
SYNTHETIC ASPECT :
1. The reaction of chalcone with guanidine hydrochloride in presence of potassium
    t-butoxide in t-butanol yielded corresponding 2-amino pyrimidine derivatives264.
2. Abd-El-galil E. Amr265 synthesised aminopyrimidines by the reaction of chalcones
    with guanidine hydrochloride in the presence of NaOH.
3. Rasaki266 synthesised 2-amino-pyrimidine by the reaction of chalcone epoxides with
    guanidine carbonate in xylene.
REACTION MECHANISM :
The reaction proceeds through conjugated addition of guinidine hydrochloride
to the α,β-unsaturated system. The bond formation take place between N-atom of












































In the first step migration of electron takes place due to the more electronegativity
of O-atom than C-atom. So carbon has positive charge while nitrogen atom looses proton
so it aquires negative charge, with simultaneous removal of water.
THERAPEUTIC IMPORTANCE
2-Aminopyrimidines exhibit a wide spectrum of pharmacological activities like,
1. Antimicrobial267,268
2. Antitumor269
3. Inhibitor of celular proliferation270




8. Tyrosine kinase Inhibitor275
9. Adrenaline α-receptor bloker276
Large no of drugs possess aminopyrimidine ring system. Well-known antimalarial
agents like trimethoprim (I) and pyrimethamine (II) possess pyrimidine ring system.
Hisaki Masakutsu277 synthesised some aminopyrimidines which are useful in the
treatment of rotaviral diseases. Robson C. et. al.278  prepared aminopyrimidine
derivatives as antifungal agents in P9P and MRP over expressive tumor cell lines. Leanne
M. et. al.279 have prepared aminopyrimidines and reported them as antiviral agent.
Yamada K 280synthesised some aminopyrimidines and tested for endothelin













antiinflammatory, anticancer, antirheumatoid activities. Gangjee A. et.  al.282 synthessied
aminopyrimidines which possess antitumor activity. Ugarkar B. et.  al.283 found
aminopyrimidines in the inhibition of cardiovascular and ceribrovascular disorders.
Hernandez et. al.284 and Secrist J.  et. al.285 prepared aminopyrimidines showing
antitumor activity. Glazier A. et. al.286 and Singh J.287 found  aminopyrimidines as
antiviral agents. Pan S.288 prepared 2-methylthio-4-amino-6-(3,5-diacetylphenyl-
amino)-pyrimidines. Which show anti HIV activity in H9 cell cultures. Aminopyrimidines
derivatives also possess antimicrobial289, antiHIV290 and antitumor291 activities.
Looking to the deversified activities exhibited and in continuation of our work on
the synthesis of biologically active heterocycles, the synthesis and biological screening
of aminopyrimidine derivatives have been described as under. Bargiotti, Alberto et. al.292
prepared 1,7-disubstituted guanine derivatives for their therapeutic use as telomerase
inhibitors & anticancer agent. Bargiatli, Alberto et. al.293 prepared disubstitute 7,9-
guaninium halides as telomerase inhibitors.
Peirre C. Wyss et. al.294 prepared some novel aminopyrimidines as novel
dihydrofolate reductase inhibitors. Aleem Gangjee et. al.295 prepared some
aminopyrimidines as potential dual inhibitors of thymidylate synthase & dihydrofalate
reductase & as potential antitumor agents. Andre Rosowasky et. al.296 prepared
aminopyrimidines as potent & selective inhibitors of dihydrofalate reductase from three
major opportunistic pathogens of AIDS. Tsutumi et. al.297 prepared aminopyrimidines
as addenosine receptor antagonists.
Looking to the interesting properties of Aminopyrimidines, we have synthesised
some new aminopyrimidines, which have been described as under.





SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-4-ARYL-6-(1’,N-
PHENYL-3’-â-PYRIDYL-1,H-PYRAZOLE-4’-YL)PYRIMIDINES
Looking to the interesting pharmacological and agriculture activity of pyrimidine
ring system, it was considered worthwhile to synthesize some new   2-Amino-4-aryl-6-
(1’,N-phenyl-3'-â-pyridyl-1,H- pyrazole-4’-yl)pyrimidine   of  type (VIII) to study
their biological activities. Amino pyrimidine derivatives have been prepared by the
reaction of the chalcones of Type (II) with guanidine hydrochloride in presence of ethanol
shown as under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and further
supported by mass spectroscopy. The mass spectra of 2-Amino-4-(p-tolyl)-6-(1’,N-
phenyl-3’-â-pyridyl-1,H-pyrazole-4’-yl)pyrimidines give m/z = 404 (recorded on Page
No. 113). The fragmentation is also explained (Page No. 114).
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The biological
activities of the synthesized compounds were compared with standard drugs.

















Alkane C-H str. (asym.) 2918 2975-2950    95
-CH3 C-H str. (sym.) 2850 2880-2860     ,,
C-H i.p.def. (asym.) 1448 1470-1435     ,,
             C-H o.o.p.def. (sym.) 1375 1390-1370     ,,
Aromatic C-H  str. 3053 3090-3030    96
C=C str. 1498 1540-1480     ,,
C-H o.o.p. (def) 815 835-810     ,,
Pyrazole C=N str. 1629 1600-1650     ,,
moiety C-N str. 1226 1230-1020     ,,
Primary amine N=H str. 3298 3559-3350    95
Pyrimidine C=N str. 1546 1580-1520    96
C-N str. 1226 1350-1200
                                 Overlapped
Type     Ref.
        Reported










































Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400cm-1
(KBr disc.)






    (δppm)
 Relative No.
  of  protons
Multiplicity Inference    J Value
    In Hz
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)




















1 2.38 3H singlet Ar-CH3     -
2 5.96 2H singlet -NH2     -
3 7.22-7.25 2H doublet Ar-Hb,b’ Jbb’=7.9
4 7.34-7.43 1H multiplet Ar-Hh     -
5 7.49-7.55 3H multiplet Ar-Hc,d,d’     -
6 7.82-7.85 2H doublet Ar-Ha,a’ Jaa’=8.1
7 7.90-7.93 2H doublet Ar-He,e’ Jee’=8.1
8 8.12-8.21 2H multiplet Ar-Hj,i     -
9 8.57-8.62 1H multiplet Ar-Hk     -
10 8.90 1H singlet Ar-Hf     -

































































































m/z = 314 (m-1)
m/z = 261 (m+1)
m/z = 251 (m-2)
m/z = 185 (m-2)
m/z = 274 (m-2)
m/z = 221 (m+2)
m/z = 77 (m-1)m/z = 91 (m-1)
m/z = 119 (m-2)
m/z = 246 (m-1)




SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-4-ARYL-6-(1’,N-
PHENYL-3’-â-PYRIDYL-1,H-PYRAZOLE-4’-YL]PYRIMIDINES
[A] Synthesis of 1,N-Phenyl-3-â-pyridyl-4-formyl pyrazole
See Part-I, Section-I (B).
[B] Synthesis of 1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-
2-propene-1-one
See Part-I, Section-II (B).
[C] Synthesis of 2-Amino-4-(p-Tolyl)-6-(1’,N-phenyl-3'-â-pyridyl-1,H-
pyrazole-4’-yl)pyrimidine
A mixture of  1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-2-propen-
1-one  (3.65 g, 0.01 M) and guanidine hydrochloride (1.10 g, 0.01M) was refluxed in
ethanol on a water bath for 4-5 hrs. The reaction mixture was poured in to crushed ice.
The product was filtered and crystallized from ethanol. Yield 47%, m.p. 256°C. Anal.
Calcd. for C25H20N6 ; Required: C, 74.24; H, 4.98; N, 20.78 %; Found: C, 74.19;
H, 4.95; N, 20.76%.
Similarly other 2-Amino-4-aryl-6-(1’,N-phenyl-3'-â-pyridyl-1,H- pyrazole-4’-yl)
pyrimidines  were prepared. The physical data are recorded in Table No. 7.
[D] Antimicrobial activity of  2-Amino-4-aryl-6-(1’,N-phenyl-3'-â-pyridyl-1,H-
pyrazole-4’-yl)pyrimidines
Antimicrobial testing were carried out as described in Part-I Section-II (C). The
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Historically, a wide range of biological activities have been attributed to pyridine
derivatives. Pyridine-3-carboxamide occurs as a component of  the structure of  the
important coenzymes NADP + (I), one of the B2 complex of vitamins, occurs in red
blood carpuscles and participates in biochemical redox reaction. Pyridoxal (Vitamin B6)
(II), occurs in yeast and wheatgerm is an important food additive.
The availability of 3-cyanopyridine, nicotinamide and nicotinic acid make possible
their use as synthetic intermediates.
SYNTHETIC ASPECT
Different methods for the preparation of 3-cyanopyridines are available in
literature298-304.
Sakurai and Midorikwa305,306 have reported that malononitrile reacts with
a,bunsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines (III).
MECHANISM:
The reaction proceeds through conjugated addition of active methylene






































The cyanopyridine derivatives are extensively used in medicine, due to its
antidiabetic, antihypertensive, anticholestemic, antifungal and antibacterial properties.













Gangjee et. al.319 have synthesised some novel cyanopyridine derivatives of



























R’ = H, 2-OMe, 4-OMe, 4-Cl
Z = -NH, -N-CH3
(IV)
The insecticidal activity of cyanopyridines has been screened by Y. Sasaki et.
al.320 Umed Ten et. al.321 have prepared cyanopyridines as agrochemical fungicides.
The oxide activator bleaching activity of cyanopyridine has been proved by Rees M.322
Oshida Mario323 prepared cyanopyridine derivatives which inhibit cerebral edema and
delayed neuron death. Hence, they are useful as cerebral edema inhibitors as
cerebrovascular disorder remedies.
Several co-workers have prepared some novel cyanopyridine derivatives and
reported their cholinesterase inhibitors324, antihistaminic and antiallergic325,
adernegic326, herbicidal327, antiinflammatory328, and insecticidal329 activities.
Chambers et al.330 have synthesised new carbonyl substituted pyridine derivatives
(V) and prooved that they are inhibitors of phosphodiestercy (IV) isozymes.
Some new 3-cyanopyridine derivatives have been prepared by  Hammama A.











(V) R = Aryl
122
Abdallah N. et. al.332 have prepared cyanopyridine derivatives which showed
analgesic and antiinflammatory activity. Ladouceur Getan H. et. al.333 have synthesised
some new pyridine derivatives behaving as glucagon antagonist. Caroline Charlie and
co-worker334 have prepared pyridine derivatives having antiinflammatory activity.
Antimicrobial activity of 3-cyanopyridine derivatives have been studied by Mona Komel
et. al.335
CONTRIBUTION FROM OUR LABORATORY
H. H. Parekh et. al.336-337 have synthesised the series of cyanopyridines and
postulated them as antimicrobial agents. A. R. Parikh et. al.338 have prepared some
new cyanopyridines and studied their antimicrobial activity. H. H. Parekh et. al.339have
synthesised 3-cyanopyridines bearing quinoline nucleus and tested their antimicrobial
and antitubercular activity.
In view of the above observations, the synthesis of new 3-cyanopyridine
derivatives bearing 1N-Phenyl-3-β-pyridyl-4-formyl pyrazol moiety, were aimed at
investigating biological activities of these compounds.





SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-3-CYANO-4-
[1’,N-PHENYL-3’-â-PYRIDYL-PYRAZOL-4’-YL]-6-ARYL PYRIDINES
In the past years, considerable evidence has been accumulated to demonstrate
the efficiency of cyanopyridines. To further assess the potential of such a class of
compounds cyanopyridine derivatives of type (IX) have been synthesised by condensation
of malononitrile and ammonium acetate with 1-aryl-3-(1',N-phenyl-3'-β-pyridyl-pyrazol-
4’- yl)-2-propen-1-ones.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also. The mass spectra of 2-amino-3-cyano-4-[1’,N-phenyl-3’-â-pyridyl-
pyrazol-4’-yl]-6-(p-tolyl) pyridines  give m/z = 428 (recorded on Page No. 126). The
fragmentation is also explained (Page No. 127).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological
activity of synthesised compounds were compared with standard drugs.
















Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2916 2995–2920 95
 –CH
3
C – H str. (sym.) 2854 2880–2850 "
C – H i.p. (def.) 1446 1470–1435 "
C – H o.o.p. (def.) 1342 1385–1330 "
Aromatic C – H str. 3058 3080–3010 96
C – H i.p. (def.) 1018 1110–1000 "
C – H o.o.p (def.) 829 835–810 "
Pyrazole C = N str. 1589 1650–1600 96
moiety C = C str. 1531 1585–1480 "
C – N str. 1292 1350–1200 "
Pyridine C = C  str. 1589 1650-1520 95
                                      Overlapped
N- H str. 3354 1075–1020 "
N- H def. 1589 1075–1020 "
C ≡ N str. 2218 2240-2210 "






























    Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)





    (δppm)
 Relative No.
  of  protons
Multiplicity Inference
1 3.9 3H singlet Ar-OCH3     -
2 6.97-7.0 2H doublet Ar-Haa’ Jaa’=8.8
3 7.40 1H singlet Ar-Hl     -
4 7.51-7.54 2H doublet Ar-Hbb’ Jbb’=8.1
5 7.61-7.65 1H multiplet Ar-Hh     -
6 7.79-7.84 2H doublet Ar-Hdd’ Jdd’=8.0
1H multiplet Ar-Hc     -
7 7.98-8.01 2H doublet Ar-Hee’ Jee’=8.8
8 8.24-8.27 1H doublet Ar-Hjk Jjk=7.8
9 8.41 1H singlet Ar-Hf      -
10 8.71-8.73 1H doublet Ar-Hk Jkj=6.00
11 9.1 1H singlet Ar-Hg      -
   J Value






















































































m/z = 351 (m-2)
m/z = 209
m/z = 247 
m/z = 221
m/z = 131 (m+2)
m/z = 336 (m+2)m/z = 104 (m+2)
m/z = 262 (m+1)




m/z = 119 (m+2)


























SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-3-CYANO-4-
[1’,N-PHENYL-3’-â-PYRIDYL-PYRAZOL-4’-YL]-6-ARYL PYRIDINES
[A] Synthesis of 1,N-Phenyl-3-â-pyridyl-4-formyl pyrazole
See Part-I, Section-I (B).
[B] Synthesis of 1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-
2-propen-1-one
See Part-I, Section-II (B).
[C] Synthesis of 2-Amino-3-cyano-4-[1',N-phenyl-3'-â-pyridyl-pyrazol-
4'-yl]-6-(p-tolyl) pyridine
A mixture of 1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-
2-propen-1-one (3.65 g, 0.01 M), malononitrile (0.66 g, 0.01 M) and ammonium
acetate (6.61g, 0.08M) dissolved in absoulte alcohol was refluxed for 10 hrs. at to
m.p. 60-70oC.  The reaction product was poured into ice, crude product was isolated,
crystallised from  ethanol. Yield 65%, m.p. 230oC (C27H20N6 ; Found : C, 75.59%;
H, 4.65%; N, 19.58%; Requires : C, 75.68%; H, 4.70%; N, 19.61%).
Similarly other cyanopyridines have been obtained. The physical data are recorded
in Table No. 8.
[D] Antimicrobial activity of 2-Amino-3-cyano-4-[1',N-phenyl-3'-â-
pyridyl- pyrazol-4'-yl]-6-aryl pyridines
Antimicrobial testing was carried out as described in Part-I, Section-II (C). The
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Thiosemicarbazones, also known as amino derivatives of thiourea, have found
their way into almost every branch of chemistry, commercially they are used as dyes,
photographic films, plastic and in textiles industry. Thiosemicarbazones are  extensively
used in medicinal chemistry.
SYNTHETIC ASPECT
The reaction between thiosemicarbazide and carbonyl compound have aroused
a great attention because of the interesting nature of resulting compounds for their uses
in medicine.
Different methods for the synthesis of thiosemicarbazones are available in
literature.340-343
1.  A. B. Tomchin344 has synthesised thiosemicarbazones by the recyclisation  of
2-amino-5-(2-aminoaroyl)-1,3,4-thiadiazoles.
2. A. K. Bhatt and co-workers345 have synthesised thiosemicarbazones by the
condensation of chalcones with thiosemicarbazide.
THERAPEUTIC IMPORTANCE

































Kalyan C. N. and co-workers359 have synthesised 1-(p-benzoylamino)-benzoyl-
4-substituted thiosemicarbazone derivatives and screened for their antimicrobial activity.
Siatra T. and co-workers360 have prepared some new thiosemicarbazones from 3-
acetyl indole and reported their effect on DNA synthesis and cell proliferation.
Li Jun et. al.361 has preped some new 3-amino pyrimidine-2-carboxaldehyde
thiosemicarbazone derivatives and reported them as novel prodrug forms of
ribonucleotide reductase inhibitors. Fedorova O. V. and coworkers362have synthesised
some new thiosemicarbazones (II) exhibiting good in vitro tuberculostatic activity.
Anticancer activity of thiosemicarbazone derivatives (III) have been reported by Krezel
Izabella.363
W. Deteng and co-workers364 have prepared thiosemicarbazones (IV) and
documented their usefulness as sodium channel blockers.
Magalhaes N. et. al.365 have synthesised some new thiosemicarbazones and
reported their anticancer activity. Toxicity and fungiocity of some novel thiophene-2-
carboxaldehyde thiosemicarbazones have been evaluated by Teoh-Siang-Guan et. al.366




























Rajasekaran A. and co-workers368 have prepared some new  thiosemicarbazone
(V) and reported their antimicrobial activity.









Thus the important role displayed by thiosemicarbazones for various physiological
activities prompted us to prepare a series of thiosemicarbazones having pyrazole nucleus
as parent molecule which has been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-
  ARYL-3-(1’,N-PHENYL-3’-â-PYRIDYL-PYRAZOL-4’-YL)-2-
  PROPENE-1-THIOSEMICARBAZONES
SECTION-II : MICROWAVE INDUCED AN EXPENDITOUS SYNTHESIS
   OF 1-ARYL-3-(1’,N-PHENYL-3’-â-PYRIDYL-PYRAZOL-










SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1’,N-PHENYL-
3’-â-PYRIDYL-PYRAZOL-4’-YL)-2-PROPENE-1-THIOSEMICARBAZONES
In the past years, considerable evidence has been accumulated to demonstrate
the efficiency of thiosemicarbazones. To further assess the potential of such a class of
compounds, thiosemicarbazones of type (X) have been prepared by the condensation
of 1-aryl-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-2-propen-1-ones  with
thiosemicarbazide.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also. The mass spectra of 1-(p-Tolyl)-3-(1’,N-phenyl-3’-â-pyridyl-
pyrazol-4’-yl)-2-propene-1-thiosemicarbazonegive m/z = 438 (recorded on Page No.
138). The fragmentation is also explained (Page No. 139).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological


















Type  (X) R = Aryl
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Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2921 2995–2920 95
 –CH3 C – H str. (sym.) 2837 2880–2850 "
C – H i.p. (def.) 1416 1470–1435 "
C – H o.o.p. (def.) 1360 1385–1330 "
Aromatic C – H str. 3055 3080–3010 96
C – H i.p. (def.) 1172 1110–1000 "
C – H o.o.p (def.) 812 835–810 "
Pyrazole C = N str. 1598 1650–1600 96
moiety C – N str. 1252 1350–1200 "
Amine N- H str. 3395 1075–1020 "





    (δppm)
 Relative No.
  of  protons
Multiplicity Inference
1 7.34-7.39 1H doublet Vin.Hm Jml=15.5
2 7.51-7.57 3H multiplet Ar-Hh,aa’     -
3 7.63-7.67 3H multiplet Ar-Hc,dd’     -
4 7.79-7.81 2H doublet Ar-Hbb’ Jbb’=7.5
5 7.81-7.85 1H doublet Vin.Hl Jlm=14.9
6 7.81-7.84 2H doublet Ar-Hee’ Jee’=8.3
7 8.23-8.25 1H doublet Ar-Hf     -
8 8.41 1H singlet Ar-Hk     -
9 8.71-8.73 1H multiplet Ar-Hg     -
10 9.08 1H singlet Ar-Hj Jjk=7.60
   J Value
    In Hz
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)





















































































m/z = 350 (m+2)
m/z = 337 (m+2)
m/z = 260 (m+2)
m/z = 246 
m/z = 209 (m+2)
m/z = 92
m/z = 105 (m+2)




















SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1’,N-PHENYL-
3’-â-PYRIDYL-PYRAZOL-4’-YL)-2-PROPENE-1-THIOSEMICARBAZONES
[A] Synthesis of 1,N-Phenyl-3-â-pyridyl-4-formyl pyrazole
See Part-I, Section-I (B).
[B] Synthesis of 1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-
  2-propene-1-one
See Part-I, Section-II (B).
[C] Synthesis of 1-(p-Tolyl)-3-(1’,N-phenyl-3'-â-pyridyl-pyrazol-4'-yl)-
  2-propene-1-thiosemicarbazone
A mixture of 1-(p-Tolyl)-3-(1',N-phenyl-3'-â-pyridyl-pyrazol-4’-yl)-2-propen-
1-one (3.65 g, 0.01 M) in ethanol & thiosemicarbazide (0.91 g, 0.01 M) in ethanol (20
ml.)containing catalytic amount of acetic acid was refluxed for 8 hrs. on water bath. The
reaction mixture was then cooled and diluted with cold water, crude product was isolated,
crystallised from ethanol. Yield 58%, m.p. 120oC (C25H22N6S ; Found : C, 68.40%;
H, 5.06%; N, 19.14%; Requires : C, 68.47%; H, 5.01%; N, 19.16%).
Similarly other cyanopyrans have been obtained. The physical data are recorded
in Table No. 9.
[D] Antimicrobial activity of 1-Aryl-3-(1’,N-phenyl-3'-â-pyridyl-pyrazol-
4'-yl)-2-propene-1-thiosemicarbazones
Antimicrobial testing was carried out as described in Part-I, Section-II
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 MICROWAVE INDUCED AN EXPENDITOUS SYNTHESIS OF 1-ARYL-3-
(1’,N-PHENYL-3’-â-PYRIDYL-PYRAZOLE-4’-YL)-2-PROPENE-1-
THIOSEMICARBAZONE
The use of domestic microwave oven in this regard is now a well established
procedure in MORE370(Microwave Induced Organic Reaction Enhancement). It has
been reported that the rate of variety of organic reaction such Diels-Alder371,372,
Claisan reaction 373,374, oxidation375-376, reduction377, diacetylation378,379,
deacetylation380, esterification381, hydrolysis of esters382,383, Doebner
condensation384, Knoevenagel condensation385 could be enhanced by microwave
irradiation.
Recent days, domestic microwave oven is useful to prepare isoflavons386,
formazans387, chalcones388, quinazolinones389, benzofurans390and pyrazolines391-
394. The name reaction such as Biginelli395, Prins396, Cannizzaro397and cross
Cannizzaro398, Michael addition399, Fries migration400, Wolff-Kishner reduction401,
Gould Jacobs reaction402, Beckmann reaction403, Tendem-Fries404, Aldol405can also
be performed by domestic microwave oven.
As a part of on going research towards the non traditional approach to the
experimental setup of organic reaction, the concept of microwave enhanced reaction
has been utilized for rapid and efficient synthesis of 1-Aryl-3-(1’,N-phenyl-3’-â-pyridyl-
pyrazol-4’-yl)-2-propene-1-thiosemicarbazone. Q. Pro-M Microwave oven, Questron
technologies corporation-CANADA, sample preparation system : 220 VAC, 60 Hz is
used as a microwave irradiation source and data are compared in terms of yield and
reaction period and have been cited in Table No. 9a.
145
TABLE NO. 9a : COMPARISION OF CONVENTIONAL AND MICROWAVE
ENHANCED SYNTHESIS OF THIOSEMICARBAZONES
9a 4-CH3-C6H4- 8 58 9 62 120
9b 4-OCH3-C6H4- 8 54 10 57 134
9c 2-OH-C6H4- 8 52 9 56 180
9d 4-OH-C6H4- 8 60 9 63 186
8e 4-Cl-C6H4- 8 58 11 61 170
9f 4-F-C6H4- 8 64 9 67 154
9g 4-Br-C6H4- 8 68 10 70 206
9h 3-NO2-C6H4- 8 49 7 52 179
9i 4-NO2-C6H4- 8 45 11 48 188
















Pyrazoles are well known five membered heterocyclic compounds and several
procedure for there synthesis have been extensively studied. Such studies have been
stimulated by various promising applications, especially in the case of N-substituted
pyrazole derivatives. In fact, certain N-substituted pyrazoles are used as pharmaceuticals
e.g. analgesic, anti-inflammatory, antipyretic, agrochemicals whereas some other is being
studied for their medicinal interest.
The knowledge of such applications has pointed out that N-substituted pyrazoles
are important target to be prepared to our interest on the synthesis and molecular structure
determination of some types of pyrazoles.
The pyrazole ring system (I) consists of a doubly unsaturated five membered ring
containing two adjacent nitrogen atoms. Knorr406,407 first synthesized a compound
containing this system in 1883 by a reaction of ethylaceto acetate with phenylhydrazine,
which yield 1-phenyl-3-methyl-5-pyrazolone (II).
Knorr408 introduced the name pyrazole for these compounds to denote that the
nucleus was derived from pyrrole by replacement of carbon by nitrogen. Since many















Various methods for the preparation of pyrazoles have been cited in literature.
1. The reaction of hydrazine or its derivatives such as alkyl or aryl hydrazines,
semicarbazine or aminoguanidine with 1,3-dicarbonyl compounds.
2. The reaction of  hydrazines with α,β-unsaturated carbonyl compounds.
3. The reaction of aliphatic diazo compounds such as diazomethane or
diazoester with acetylene or olefins.
THERAPEUTIC IMPORTANCE
Much research has been carried out with the aim to finding therapeutic values of
pyrazole moiety since their discovery. A large number of substituted pyrazole derivatives
are prepared and tested for variety of biological activities like.
1.   Antiinflammatory409,410
2.   Insecticidal411
3.   p-38 Kinase inhibitors412-415
4.   Antiepileptic416
5.   Nematicidal417
6.   Antitumor418
7.   Anticancer419
8.   Antiviral420
9.   Herbicidal421-424
10. AntiHIV425










Somega Shinzo and co-workers427have synthesized pyrazole derivatives and
reported their herbicidal activity. Geheing Reinhald et. al.428 have synthesized 5-amino-
4-cyano-1-aryl-pyrazoles and shown them as plant growth inhibitors. Nakamura Katsyga
and co-worker429,430 have prepared 1,5-diphenyl pyrazoles as Cox-2-inhibitors (III).
Pier Giovanni Baraldi et. al.431have synthesized pyrazole derivatives as
antileukemic agents. Thomas Alan Crowell et. al.432 prepared new pyrazoles as selective
α-adrenergic agonists. Kevin M. Moore et. al433prepared pyrazoles as human
dopamine-D4-receptors while Bernard Banks et. al.434have synthesized pyrazole
derivatives (IV) and tested for their antiparasitic activity.
Laborde Edgardo et. al.435have found that pyrazoles possess glycine transporter-
2-inhibitor activity. Andrew Thurkaub et. al.436have synthesized high affinity C5a receptor
modulator pyrazoles. Nagaaki Sato et. al.437 have prepared pyrazoles as neuropeptide
T5 receptor antagonist. G. M. Hi Yamanonch438 has prepared pyrazoles as glycine
transporter protein inhibitors.
Feid-Allah Hassan439have prepared pyrazoles and reported their antidiabetic



























Jacques Dumas and co-workers441have synthesized pyrazole derivatives as
rafkinase and angiogenesis inhibitor agents. David L. S. et. al.442 have reported pyrazoles
as activators of the nitrile oxide receptor and soluble guanglate cyclase agent. T Van
Herk et. al.443 have demonstrate pyrazoles as nicotinic acid receptor (VI). Barber
Christopher et. al.444 have synthesized pyrazole derivatives as phosphodiesterase
inhibitors.
Recently, Atkinson R. N. et. al.445 have synthesized pyrazoles as sodium channel
Blocker (VII). Murakanii Hiroshi et. al.446 have synthesized pyrazoles as antifouling
agent. Gellibert Francoise et. al.447 have prepared pyrazole derivatives as TGF-13
inhibitors.
Grazid Mamalo et. al.448 have newly synthesized pyrazole derivatives tested for
antimicrobial activity. R. Y. Huang and co-workers449 have prepared some 1,2,4- triaryl-
4-alkyl-pyrazoles as estrogen receptor. C. Vittoria and co-workers450 have prepared
some pyrazoles as adenosine receptor antagonists.
Schindler Ursula et. al.451 synthesized new pyrazole derivatives (VIII) as
cardiovascular agents. Havaldar Freddy et. al.452 synthesized 4,5-dihydro 3-phenyl-
1H-pyrazole and reported their biological activity. Carbau Romuald and co-workers453
have prepared pyrazole derivatives (IX) useful as reverse transcriptase inhibitors for the
















Nishimura Tsoshihiro et. al.454 have synthesized pyrazoles as inhibitors of human
SGLT2 (sodium dependent glucose transporter-2). From Recent literature it has found
that pyrazole derivatives possesses a number of biological activities, such as
fungicidal,455-456herbicidal,457-460 cardiovascular,461antiinflammatory,462-464
Cox-II inhibitor,465 antimicrobial,466anticancer,467-469 protein kinase inhibitor,470-
473 antibacterial474,475antiviral,476antiparasitic,477HIV reverse transcriptase
inhibitor478,479and 5-H T2O receptors.480-482
Ji Yang et. al483 have documented 3-(4-phenoxyphenyl)pyrazole derivatives (X)
for their Sodium Channel Blockers. Ruoxi Lan et. al.484 have prepared pyrazole
derivatives as Cannabinoid receptor antagonist (XI).
Akihiko Tanitame et. al.485 have synthesized pyrazole derivatives (XII) as
antibacterial activity and selective inhibitory activity against bacterial topoisomerases.
Gregory R. Bebernitz et. al.486have described 1,3-diaryl-[1H]-pyrazole-4-acetamide
as antidiabetic agents (XIII). Franco chimenti, Adriana Bolasco et. al487have synthesized





























Abdel-rahman farghaly and hussein el-kashef et. al.488  have prepared pyrazole
derivatives as antibacterial and antifungal activities. Pierluigi caboni  et. al.489 have
reported phenylpyrazole as insecticide action(XIV). Craig W. Lindsley et. al.490have
discovered positive allosteric Modulators for the Metabotropic Glutamate Receptor from
a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor
function in vivo(XV).
Adrian l. Gill and Martyn Frederickson et. al.491have identified pyrazole as a
novel p38 MAP kinase inhibitors(XVI). Jeffrey roppe et. al.492 have discovered novel








































Literature survey reveals that the compounds bearing pyrazole moiety possess
potential drug activity. Looking to the diversified biological activity, it appeared of interest
to synthesize some á-arylaminonitriles, azomethines and thiazolidinones  bearing pyrazole
moiety, in order to achieving compounds having better therapeutic importance. These
studies are described in following parts.
STUDIES ON  PYRAZOLES :
PART - VIII : STUDIES ON á-ARYLAMINONITRILES
PART - IX : STUDIES ON N-ARYL-1,N-PHENYL -3-â-PYRIDYL-PYRAZOL-
  4-YL-AZOMETHINES
PART - X : STUDIES ON THIAZOLIDINONES





The nitriles have been widely studied because of their industrial and biological
applications. Several nitrile derivatives have been used in agriculture field becuse of
their high toxicity. The first synthesis of nitriles was reported by  Wohler and Liebig493
in 1832 and by pelouze494 in 1834. The nitriles are very useful intermediate  for various
product such as acrylonitrile for plastics, synthetic rubber, fibers  and phthalonitriles for
a dye stuff.
SYNTHETIC ASPECT
Various methods for the preparation of nitriles have been reviewed by David
Mowry.495 Few recent procedures are as mentioned below.
(I)    From halides using NaCN,  Al2O3496.
(II)   From alkyl halides using KCN, tetraalkylammonium salt and water in trace497
(III)  Preparation by metathesis498
(IV) Dehydrating amides using POCl3499
(V)  The pyrolysis of Schiff’s bases500
(VI)  A  practical method for the preparation of nitriles from primary amines under





















 From the above reaction, it can be seen that a nucleophile (CN) attacks on the
carbonyl carbon of aldehyde and yields cyanohydrine which reacts with amine to yield
nitrile derivatives.
THERAPEUTIC IMPORTANCE











Nitriles with fused pyridine rings were reported as ulcer inhibitor.514 Nobuyuki
et. al.515 have prepared some new nitriles (I) and reported them as tumor necrosis
factor production inhibitors.
Kobayashi et. al.516 have synthesised nitrile derivatives. The nitriles as a
refrigeration lubricating oil have been reported by Sabani and co-workers.517 Peterson













V. S. Parmar and co-workers519 have prepared a series of nitriles (II) and
reported them as antioxidants. Antimicrobial activity of nitriles bearing  quinoline moiety
has been  reported by  A. R. Parikh and co-workers.520
Nosyruva and co-workers521 have prepared some new nitrile derivatives (III)
and screened for their biological activities.
P. Sanna and co-workers522 have prepared some novel acrylonitriles (IV) and
studied their antituberculor activity. Catherine M. and co-workers523have prepared
some new cyanoguanidine derivatives and reported them as thromboxane receptor
antagonists.
In persuing the work on the nitrile derivatives incorporating pyrazole molecule,
the newer nitrile derivatives have been synthesised which have been described as under.























R = H, OH, Cl
156
SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF á-ARYLAMINO-1,N-
PHENYL-3-â-PYRIDYL-PYRAZOL-4-YL-ACETONITRILES
In view of the therapeutic activities of nitriles it was contemplated to synthesise
some new nitriles in search of agents possessing higher biological activity. Nitrles of
type (XI) have been synthesised by the reaction of 1,N-Phenyl-3-β-pyridyl-4-formyl-
pyrazole  with different aromatic amines by the presence of sodium cyanide and glacial
acetic acid at 0-5oC.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also. The mass spectra of α-(p-Tolylamino)-1,N-phenyl-3-â-pyridyl-
pyrazol-4-yl-acetonitriles give m/z = 337 (recorded on Page No. 159). The fragmentation
is also explained (Page No. 160).
The products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological
activities of the synthesised compounds were compared with standard drugs.
The synthesised compounds have been screened for their in vitro biological assay
like antitubercular activity towards a strain of Mycobacterium tuberculosis H37Rv at
concentration of 6.25 mg/ml using Rifampin as standard drug.





R2 - NH2, NaCN









IR SPECTRAL STUDY OF  á-(p-TOLYLAMINO)-1,N-PHENYL-3-â-PYRIDYL-
PYRAZOL-4-YL-ACETONITRILE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2920 2975–2920 95
–CH
3
C – H str. (sym.) 2866 2880–2860 "
C – H i.p. (def.) 1454 1470–1435 "
C – H o.o.p. (def.) 1357 1395–1370 "
Aromatic C – H str. 3033 3090–3030 96
C = C str. 1554 1520–1480 "
C – H i.p. (def.) 1126 1125–1090 "
1062 1070–1000 "
C – H.o.o.p (def.) 815 835–810 "
Pyrazole C = N str. 1600 1610–1590 96
moety C – N str. 1217 1230–1220 "
C = C str. 1515 1585–1480 "
Nitrile C ≡  N str. 2237 2240–2220 95






























1 2.36 3H singlet Ar-CH3     -
2 3.96 1H singlet -NH     -
3 5.40 1H singlet Ar-Hl Jbb’=7.9
4 6.71-6.74 2H doublet Ar-Ha,a’ Jaa’=8.4
5 7.10-7.13 2H doublet Ar-Hb,b’ Jbb’=6.8
6 7.31-7.40 1H multiplet Ar-Hh     -
7 7.49-7.54 3H multiplet Ar-Hc,d,d’     -
8 7.76-7.79 2H doublet Ar-He,e’ Jee’=8.2
9 8.09-8.12 1H multiplet Ar-Hj     -
10 8.36 1H singlet Ar-Hf     -
11 8.61-8.63 1H doublet Ar-Hk Jkj=6




    (δppm)
 Relative No.
  of  protons
Multiplicity Inference    J Value
    In Hz































































m/z = 91 (m-2)
m/z = 104 (m-2)
m/z = 188 (m-2)
m/z = 261 (m-2)
m/z = 247 (m-2)
m/z = 247 (m-3) m/z = 235 (m-3)
m/z = 338 (m-2)




















SYNTHESIS AND BIOLOGICAL EVALUATION OF   á -ARYLAMINO-1,N-
PHENYL-3-â-PYRIDYL-PYRAZOL-4-YL-ACETONITRILES
[A] Synthesis of 3-Acetylpyridine phenyl hydrazone
See, Part-I, Section-I (A).
[B] Synthesis of 1N-Phenyl-3-â-pyridyl-4-fromyl-pyrazole
See, Part-I, Section-I (B).
[C] Synthesis of  á-(p-Anisylamino)-1,N-phenyl-3-â-pyridyl-pyrazol-4-yl-
acetonitrile
1N-Phenyl-3-β-pyridyl-4-formyl pyrazole (2.65g, 0.01M) dissolved in ethanol
(20 ml) was added to sodium cyanide (0.48g, 0.01M) dissolved in water (5 ml) followed
by glacial acetic acetic acid (5 ml). The contents were then stirred for 5 minutes to form
cyanohydrin at 0oC. p-Anisidine (1.23g, 0.01M) dissolved in methanol was added to
the reaction mixture, contents were kept at room temp. for 24 hrs. and poured into ice.
The solid product was crystallized from DMF. Yield, 57%, m.p. 199oC (C23H19N5O;
Found : C, 68.43%; H, 4.15%; N, 18.33%; Requires : C, 68.48%; H, 4.18%; N,
18.36%).
Similarly, other nitriles were prepared. The physical constants are recorded in
Table No.10.
[D] Antimicrobial activity of á-Arylamino-1,N-phenyl-3-â-pyridyl-pyrazol-
4-yl-acetonitriles
Antimicrobial testing was carried out as described in Part-I, Section-II (C). The
zone of inhibition of the test solution are recorded in Graphical Chart No. 10.
Antitubercular  screening of the compounds of type(XI) were carried out by
TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-II
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Rv >6.25 0 - "




























































Rv >6.25 0 - "
RKP-54 295722 2-NO
2




















Azomethine derivatives have been found to be potent drug in pharmaceutical
industries and possess a wide spectrum of biological activity. Azomethines are also
known as Schiff’s base and they are well known interemediate for the preparation of
azetidinone, thiazolidinone, formazone, arylacetamide and many other derivatives.
These are the compounds contain characteristic -C=N group. Holla, B. S. et. al.524
















Azomethines are obtained mainly by warming the aldehyde & aromatic amine
togethar. However, it is more convenient to work in a solvent such as alcohol, dilute
acetic acid or glacial acetic acid. Some time the reaction is aided by traceof acid in
other cases the hydrochloride of the amines can be used in the synthesis.
In general Schiff’s bases do not react further with either of the reagents used in
their preparation as do most of the other types of simple intermediates.
SYNTHETIC ASPECT :
1.   General account of the summary of reaction of aldehydes with amine (aromatic  or
      alipharic) has been reviewed by Murray.525
 R-CHO R'-NH2 R-CH=N-R'+
2.  Strache526 and Van Alphen527 have prepared imine involves in two steps.
       a.  Addition of the amine to the carbonyl group of the aldehyde gives aldol.
 The aldol is rerely capable of isolation.
 R-CHO R'-NH2+ R-CHOHNHR'
(I)
167
b. The loss of water to give an imine (azomethine), this corresponds to
the “crotonaldehyde stage” of the aldol condensation.
R-CH=N-R'R-CHOHNHR' + H2O
3. Oddo & Tognacchini528 have introduced the comparative rates of formation
of Schiff’s base from aniline & substituted aniline & aromatic aldehyde using
a cryscopic method follow the course of reaction.
Smalders, et. al.529 synthesized some new azomethine  to give potential antitumor
reagent phosphonates. Yadawe M. S. and Patil S. A.530 have synthesized azomethine
derivative of type shown as below.
Mehta R. H. and et. al.531 have synthesized coummarin schiff’s base derivatives
of type (II) and examined for their antibacterial activity.
Khalafallah A. K. and Hassan M. E.532 have prepared some styryl Schiff’s
bases spiro derivatives as potential antibacterial and antifungal activity. Sharaf El-Din,
and Nabaweyal533 have synthesized some azomethine derivatives (III) having good
antibacterial activity.
Chohan et. al.534 have synthesized azomethines, which have been  screened and
compared for their antibacterial action against bacterial  species Escherichia coli,
Pesudomonus aeruginoase and Klebisella  pneumoniase.
Das Joydip & Singh, Anilk535 have synthesized azomethine shown as below.
R  =   Ph, 4-Br-C6H4, 4-NO2-C6H4,
          2-Cl-C6H4CONH
R  =   3,4 -OH, 3, 4-NO2
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But
Me Me MeMe
All-trans-N-refinylidene-n-butylamine (IV) can be stabillized in liposomes of
phophatidylcholine. The rate of formation of the Schiff’s base is found to decrease with
increasing cholesteral concentration in the membrane.
Deshmukh M. D. and Doshi A. G.536 prepared some new  Schiff’s bases show
good antimicrobial activity against test organism S. aureus, E. coli, Saigella dysenteridse
and salmonella typhi.
Wang, Yangang; Ye, Wenta; Yang, Jun;Lou,Aihony537havesynthesize
dazomethines having good plant hormone activity. Das Arima et. al.538 have prepared
Schiff’s bases of  aminohydroxy guanidine (SB-AHG5) were tested  for antiviral  activity
against herper simplex virus type I (HSV-1) and adenovirus type-5 (Ad-5)  alone with
11 other heterocyclic SB-AHG5 some compounds has good  antiadenoviral activity.
Solankee Anjani; Mistry, Pankaj; Patel V. M.539 have synthesized some new
Schiff’s bases having good antibacterial activity.
Ram, Tilak et. al.540 have synthesized some Schiff’s bases, thiazolidinones 4-
triazolines, and formazones of 2-chloro phenothiazines and screened against carrageenin-
induced edema in albino rats. The thiazolidinones showed promising antiinflammatory
activity.
Ali, yousif et. al.541 have synthesized some Schiff’s base derivatives of glucose
contg. acetylenic bond were also prepared Hydroxybenzaldehydes were first  converted
to o-prop-2-ynyl-benzaldehydes followed by their condensation with glucosamine. The




Cascaval Alexandru; et. al.542 have synthesized azomethines, which have good
analgesic and antipyratic properties. Pandeya S. N. et. al.543 have synthesized Schiff
bases showed good activity against vibrio cholerae non-o., shigella boydii, Enterococcus
faecalis and Edwaredsiella torla with mic in the rang of 10-25 µg/ml. Some compounds
were found to be active against salmonellalyphi and vibro  cholerae-0, (mic 25-150 µg/
ml).
Omar and et. al.544 have determined cyclocondensation of azomethines  having
good antischistosomal activity.
Pawar R. P. et. al.545 have synthesized azomethines by the condensation of
iodovanillin with different substituted aromatic amines. The good antibacterial activity
was determined.
Chohan and co-workers546 have synthesized a novel class of acetyl ferrocene
derived Schiff bases possess antimicrobial activity.
Ergenc and co-workers547have synthesised azomethine derivatives having
antifungal activity.
Holla B. S. et. al.548 have prepared mannich bases. Pandey, Taruna et. al.549
prepared azomethines and their boron complexes and screened for their antifungal  and
antibacterial properties. It is evident that azomethines alone were quite toxic but their
activity increased after complexation.
Yadav Bodke & S. S. Sangapure550 have synthesised some azomethines and
tested for their biological activity. B. Shivarama Holla et. al.551 have prepared some
new Schiff’s bases having anticancer activity. Ravindra V. Chambhare et. al.552 have
prepared some azomethines of type and tested for their antimicrobial activity. B. Shivarama
Holla., et. al.553 have synthesized azomethines of type (V) having antibacterial and
anti-inflammatory activity.











Looking to the interesting properties of azomethines, we have synthesised
some new azomethines, which have been described as under.
SECTION-I : SYNTHESIS     AND        BIOLOGICAL        EVALUATION
OF  N-ARYL-1,N-PHENYL -3-â-PYRIDYL-PYRAZOL-4-YL-
AZOMETHINE





SYNTHESIS AND BIOLOGICAL EVALUATION OF N-ARYL-1,N-PHENYL -
3-â-PYRIDYL-PYRAZOL-4-YL-AZOMETHINES
The growing patent literature of recent years demonstrates that the azomethine
derivatives are used as better therapeutic agents. In view of these findings, it appeared
of interest to synthesise Schiff’s base of the type (XII) by the condensation of 1,N-
Phenyl-3-â-pyridyl-4-formyl pyrazole  with various aromatic amines in order to study
their biodynamic behavior.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also. The mass spectra of N-(p-Tolyl)-1,N-phenyl -3-â-pyridyl-pyrazol-4-yl-
azomethine give m/z = 337 (recorded on Page No.174). The fragmentation is also
explained (Page No. 175).
The products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological












Type (XII)       R = Aryl
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IR SPECTRAL STUDY OF N-(p-TOLYL)-1,N-PHENYL -3-â-PYRIDYL-PYRAZOL-
4-YL-AZOMETHINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2914 2975–2920 95
–CH
3
C – H str. (sym.) 2860 2880–2860 "
C – H i.p. (def.)                     1448 1470-1435        “
C – H o.o.p. (def.) 1377 1395–1370 "
Aromatic C – H str. 3072 3090–3030 96
C – C str. 1571 1585-1570
C – H i.p. (def.) 1124 1125–1090 "
C – H o.o.p (def.) 823 835–810 "
Pyrazole C = N str. 1571 1610–1590 96
moety C – N str. 1234 1230–1220 "










    (δppm)
 Relative No.
  of  protons
Multiplicity Inference    J Value
    In Hz
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)
PMR SPECTRAL STUDY OF   N-(p-TOLYL)-1,N-PHENYL -3-â-PYRIDYL-
PYRAZOL-4-YL-AZOMETHINE
1 2.36 3H singlet Ar-CH3     -
2 7.11-7.14 2H doublet Ar-Haa’ Jaa’=8.2
3 7.18-7.21 2H doublet Ar-Hbb’ Jbb’=8.3
4 7.35-7.45 1H multiplet Ar-Hh     -
5 7.49-7.54 3H triplet Ar-Hc,d,d’     -
6 7.82-7.85 2H doublet Ar-Hee’ Jee’=8.9
7 8.11-8.14 1H multiplet Ar-Hj     -
8 8.51 1H singlet           Ar-Hf     -
9 8.67-8.70 1H d,d Ar-Hk Jkj=6
Jkh=1.2
10 8.76 1H singlet Ar-Hl     -


















































































m/z = 247 (m+1)
m/z = 232 (m+2)
m/z = 218 (m+2)
m/z = 169 
m/z = 144
m/z = 91 
m/z = 116 (m+2)





















SYNTHESIS AND BIOLOGICAL  EVALUATION OF N-ARYL-1,N-PHENYL -3-
â-PYRIDYL-PYRAZOL-4-YL-AZOMETHINES
[A] Synthesis of 3-Acetylpyridine phenyl hydrazone
See, Part-I, Section-I (A).
[B] Synthesis of 1N-Phenyl-3-â-pyridyl-4-fromyl pyrazole
See, Part-I, Section-I (B).
[C] Synthesis of  N-(p-Tolyl)-1,N-phenyl -3-â-pyridyl-pyrazol-4-yl-azomethine
 A mixture of 1N-Phenyl-3-β-pyridyl-4-formyl-pyrazole (2.65g, 0.01M) and p-
toludine dissolved in ethanol (20 ml) was refluxed in ethanol (95%) for 6 hrs. gl.acetic
acid is used as catalyst. The contents were cooled and product isolated was crystallised
from ethanol. Yield, 75%, m.p. 222oC (C22H18N4; Found : C, 78.03%; H, 5.31%; N,
16.53%; Requires : C, 78.08%; H, 5.36%; N, 15.56%).
Similarly, other nitriles were prepared. The physical constants are recorded in
Table No. 11.
[D] Antimicrobial activity of N-aryl-1,N-phenyl -3-â-pyridyl-pyrazol-4-yl-
azomethines
Antimicrobial testing was carried out as described in Part-I, Section-II (C). The
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYLAMINOMETHYL-
3-â-PYRIDYL-1,N-PHENYLPYRAZOLE
Aminomethyl derivatives of heterocyclic compounds are associated with diverse
biological  activity. These finding prompted us to synthesise some representative
aminomethyl derivative of type (I) bearing pyrazole moiety obtained by  selective
reduction of (imine group) of Schiff’s bases of  type (XII) with  sodium borohydride in
controlled experimental condition as shown in the reaction  scheme.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also. The mass spectra of 4-p-Tolyl-aminomethyl-3-â-pyridyl-1,N-
phenylpyrazole give m/z = 340 (recorded on Page No. 183). The fragmentation is also
explained (Page No. 184).
The products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological












Type (XIII)       R = Aryl
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Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2912 2975–2920 95
–CH
3
C – H str. (sym.) 2831 2880–2860 "
C – H i.p. (def.) 1407 1470–1405 "
C – H o.o.p. (def.) 1382 1395–1370 "
Alkane C – H str.(asym.) 2912 2936-2916 "
–CH
2
C – H def. 1496 1485-1445 "
Aromatic C – H str. 3062 3090–3030 96
C – C str. 1593 1585-1570
C – H i.p. (def.) 1168 1175–1090 "
C – H o.o.p (def.) 817 835–810 "
Pyrazole C = N str. 1571 1610–1590 96










    (δppm)
 Relative No.
  of  protons Multiplicity
Inference    J Value
    In Hz
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)
PMR SPECTRAL STUDY OF 4-(p-TOLYL)-AMINOMETHYLENE-3-â-PYRIDYL-1N-
PHENYLPYRAZOLE
1 2.26 3H singlet Ar-CH3     -
2 4.34 2H singlet -CH2(A1&A2)     -
3 6.62-6.65 2H doublet Ar-Haa’ Jaa’=8.5
4 7.02-7.05 2H doublet Ar-Hbb’ Jbb’=8.2
5 7.31-7.36 1H triplet Ar-Hj Jjk=7.6
Jjh=7.3
6 7.46-7.49 2H doublet Ar-Hdd’ Jdd’=8.3
7 7.49-7.52 1H multiplet Ar-Hc     -
8 7.72-7.75 2H doublet Ar-Hee’ Jee’=8.9
9 8.05 1H singlet Ar-Hf     -
10 8.37-8.40 1H doublet Ar-Hk Jkj=8.1
11 8.53-8.56 1H doublet Ar-Hh Jhj=6.0












































































m/z = 249 (m+1)
m/z = 234 (m+1)
m/z = 217 (m+2)
m/z = 156 (m+2)
m/z = 142 (m+2)
m/z = 130 (m+2)
m/z = 117 (m+2)






















SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYLAMINOMETHYL-
3-â-PYRIDYL-1,N-PHENYLPYRAZOLES
[A] Synthesis of 3-Acetyl pyridine phenyl hydrazone
See, Part-I, Section-I (A).
[B] Synthesis of 1N-Phenyl-3-â-pyridyl-4-fromyl pyrazole
See, Part-I, Section-I (B).
[C] Synthesis of 4-Arylaminomethyl-3-â-pyridyl-1N-phenylpyrazole
 Sodium borohydride (0.15M, 0.57g) was added to a methanolic solution of
4-(p-Tolyl)amino methyl-3-β-pyridyl-1,N-phenyl pyrazole (0.01M, 3.38 g) over
a period of  30 minutes at temperature 5-10oC. The reaction mixture  then kept over
night at room temp. The excess borohydride was neutralized by adding water and
the product was extracted with ether. The ether extract was washed with water untill
neutral, then dried over anhydrous Na2SO4 and finally  the ether  was evaportated  to
give aminomethyl derivatives.  Yield, 60%, m.p. 136oC (C22H20N4; Found : C,
77.59%; H, 5.90%; N, 16.44%; Requires : C, 77.62%; H, 5.92%; N, 16.46%).
Similarly, other nitriles were prepared. The physical constants are recorded in
Table No. 12.
[D] Antimicrobial activity of 4-Arylaminomethyl-3-â-pyridyl-1,N-
phenylpyrazoles
Antimicrobial testing was carried out as described in Part-I, Section-II (C). The
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Thiazolidinones, which belong to an important group of heterocyclic compounds
have been extensively explored for their applications in the field of medicine.
Thiazolidinones, with a carbonyl group at position 2 in structure (I) and position 4 or 5
in structure(II) have been subjected for extensive study in the recent past. Numerous
reports have appeared in the literature which highlight their chemistry and use.
4-Thiazolidinones are derivatives of thiazolidine with carbonyl group at   4-
position (II). Substituent in the 2, 3 and 5 positions may be varied, but the greatest
different in structure and properties is exerted by the groups attached to carbon atom at
the 2-position and to nitrogen atom at the 3-position. The cyclic structure was assigned
after recognition of mercaptoacetic acid as a primary product of hydrolysis of 3-phenyl-
2-phenylimino-4-thiazolidinones.554
A well known antibiotic, actithiazic acid (IV), isolated from a species of
streptomyces shows specific in vitro activity against M. tuberculosis, but it is inactive
in vivo probably due to antagonisation by biotin, bears the 4-thiazolidinone skeleton
SYNTHETIC  ASPECT
Several methods for the preparation of 4-thiazolidinones are narrated in
literature555-563
1. R. Nath and K. Shanker564 have prepared 4-thiazolidinones by cyclization of
N-aryl-N’-(2'-pyridyl)-thiocarbamide with chloroacetic acid.















2. I. D. Shah and J. P. Trivedi565 have synthesized thiazolidinones from 4-aryl
thiosemicarbazones by condensing them with chloroacetic acid, α-bromo
propionic and α-bromophenyl acetic acid.
























































The reaction of 4-thiazolidinones proceeds by the attacks of the chloroacetic
acid upon the C=S group, the tautomerism takes place with removal of HCl followed by
removal of water and subsequent cyclization.
THERAPEUTIC IMPORTANCE
Much research has been carried out with the aim to finding therapeutic values of
thiazolidinone moiety since their discovery. The thiazolidinones, substituted at 2 and 3
position are reported to exhibit a wide variety of biological activities.
1.  Antibacterial567,568
2.  Antitubercular569,570












































Pawar and co-workers592 reported synthesis and in vitro antibacterial activity
of some 4-thiazolidinone derivatives. Goel et. al.593 have synthesized thiazolidinone
derivatives and compared their antiinflammatory activity, ulcerogenic liability,
cardiovascular and CNS effects. In other study, some thiazolidinones have been found
to be promising antibacterial agent.594,595
Siddique, Mohammed et. al.596 have prepared substituted thiazolidinones (IV)
and reported their antibacterial, antifungal, antithyroid and amoebicidal properties.
Akama Tsutoma et. al.597 have synthesized thiazolidinones as a Telomeres
inhibitors. S. Guniz Kucukguzel et. al.598 have synthesized thiazolidinones as
antimicrobial and anticancer agent. S. K. Srivastava et. al.599 have prepared new
thiazolidinones as antibacterial, antifungal, analgesic and diuretic agents.
Recently, Fujiwara Norio et. al.600 have synthesized thiazolidinones as
antiinflammatory agent. Pfahl Magnus et. al.601 have reported thiazolidinones and tested
their phosphatase inhibitory and anticancer activity. Jag Mohan et. al.602have prepared











R2, R4, R5 = H
R3 = Me
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Govindarajan R. et. al.603 have synthesized thiazolidinones as antitubercular,
antifungal and antibacterial agent. Dinh T. H. et. al.604 have prepared and reported
antibacterial and antifungal activity of thiazolidinones. Takagi Masae and co-workers605
have synthesized thiazolidinones and screened for their antiinflammatory activity. Ma
Tonghui et. al.606 have documented thiazolidinones as CFTR (cystic fibrosis
transmembrane conductance regulator) inhibitor.
Hassan et. al.607 have prepared 2-imino-4-thiazolidinones which have been found
to possess antimicrobial activity. K. Mogilaiah and co-workers608,609 isolated some
4-thiazolidinone derivatives and tested their antibacterial activity. G. S. Godaginamath
et. al.610 also prepared thiazolidinone derivatives as antimicrobial agent. R. S. Lodhi
and co-workers611 have been synthesized and studied antimicrobial, antiinflammatory
and analgesic property of 4-thiazolidinone and arylidene derivatives (VI).
Recently, Dayam R. et. al.612 have reported some novel thiazolidinone derivatives
as novel class of HIV- integrase inhibitors. Sonawane N. D. et. al.613 have synthesized
some new thiaolidinone derivatives as in vivo pharmacology and antidiarrheal efficacy
of a thiazolidinone CFTR inhibitor in rodents. Shih M. H. et. al.614 have described the
syntheses and evaluation of antioxidant activity of sydnonyl substituted thiazolidinone

























and thiazoline derivatives(VII). Reigada D. et. al.615 have reported some novel
thiazolidinone derivatives as release of ATP from retinal pigment epithelial cells involves
both CFTR and vesicular transport.
Moreover, Rao A. et. al.616 have described some novel thiazolidinone derivatives
as 2-(2,6-dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside
HIV-1 reverse transcriptase inhibitors. Muanprasat C. et. al.617 have prepared some
new thiazolidinone derivatives as CFTR inhibitors.
Furthermore, Salinas D. B. et. al.618 documented the thiazolidinone derivatives
as CFTR inhibitor. Wang X. F. et. al.619 have synthesized some novel thiazolidinone
derivatives described as new cystic fibrosis transmembrane conductance regulator
inhibitor on Cl-conductance in human sweat ducts. Ur F. et. al.620 have constructed
some new 6-methylimidazo[2,1-b]thiazole-5-carbohydrazide derivatives and their
antimicrobial activities.
Recently, Maclean D. et. al.621 have reported thiazolidinone library as agonists
of the follicle stimulating hormone receptor (VIII). Thiagarajah J. R. et. al.622 have











Thiagarajah J. R. et. al.623 have been reported as intestinal ion and fluid secretion
by a small-molecule CFTR inhibitor. Taddei A. et. al.624  have been constructed some
new thiazolidinone as CFTR inhibition.
These valid observations led us to explore thiazolidinones chemistry by synthesizing
its derivatives bearing pyrazole moiety of medicinal value in order to achieve better
therapeutic agents. It has been described in the following section.
SECTION - I SYNTHESIS AND BIOLOGICAL EVALUATION OF
2-ARYLIMINO-5(H)-4-THIAZOLIDINONES















SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-5(H)-4-
THIAZOLIDINONES
Looking to the interesting therapeutic activities of thiazolidinones, we have
synthesised thiazolidinone of type- (XIV)  by action of substituted aryl thiosemicarbazone
with chloroacetic acid, sodium acetate in the presence of gl. acetic acid.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy. The mass
spectra of 2-(3,4Dicholorphenylimino)-5(H)-4-thiazolidinone give m/z = 261(recorded















IR SPECTRAL STUDY OF  2- (3’ ,4’ -DICHLOROPHENYLIMINO)-5(H)-4-
THIAZOLIDINONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2933 2975–2950 426
–CH
3
C – H str. (sym.) 2835 2880–2860 "
C – H i.p. (def.) 1450 1470–1435 "
C – H o.o.p. (def.) 1361 1385–1350 "
Aromatic C – H str. 3049 3130–3030 427
C = C str. 1502 1585–1480 "
C – H i.p. (def.) 1064 1125–1090 "
C – H o.o.p. (def.) 833 835-810 "
Pyrazole C = N str. 1606 1650–1580 428
moiety C – N str. 1259 1350–1200 "
C – F 752 760-710 "
Ether C – O – C str. (asym). 1220 1275–1200 "
C – O – C str. (sym). 1029 1075–1020 "







 PMR SPECTRAL STUDY OF  2-(2’,5’-DICHLOROPHENYLIMINO)-5(H)-4-
 THIAZOLIDINONE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (d ppm) of Protons In Hz
1. 3.98 2H singlet -CH2 -
2. 7.05 1H singlet Ar-Hc -
3. 7.07-7.11 1H double Ar-Hb Jba = 8.7
doublet









































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-5-(1’,N-
PHENYL-3’-â-PYRIDYL-PYRAZOL-4’-YL-METHINO)-4-THIAZOLIDINONES
With a view to getting better therapeutic agents and considering the association
of various biological activities of thiazolidinone heterocycles, the preparation of arylidenes
of Type (XIV) have been undertaken by the condensation of 1,NPhenyl-3-(â-pyridyl)-




















Type - (XV) R = Aryl
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also. The mass spectra of 2-p-Anisylimino-5-(1’,N-phenyl-3’-â-pyridyl-
pyrazol-4’-yl-methino)-4-thiazolidinone give m/z =450(recorded on Page No. 204).
The fragmentation is also explained (Page No. 205).
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological
activities of synthesised compounds were compared with standard drugs.
202
 Observed
Alkane C-H str. (asym.) 2922 2975-2925 95
-CH3 C-H str. (sym.) 2854 2880-2860  ,,
C-H i.p.(def.) 1438 1470-1435  ,,
C-H o.o.p. (def) 1357 1395-1370  ,,
Aromatic C-H  str. 3031 3090-3030 96
C=C str. 1502 1540-1480  ,,
C-H i.p.(def.) 1095 1125-1090  ,,
C-H o.o.p.(def) 831 835-810  ,,
Pyrazole C=N str. 1598 1600-1650 72
moiety C-N str. 1226 1220-1020  ,,
Thiazolidinone C=O str. 1706 1760-1655 95
ring C-S-C str. 688 700-600  ,,
C-N str. 1164 1220-1020  ,,
C=N str. 1639 1640-1590  ,,
Type     Ref.
        Reported


































IR SPECTRAL STUDIES OF 2-(p-TOLYLIMINO)-5-(1’,N-PHENYL-3’-â-
PYRIDYL-PYRAZOL-4’-YL-METHINO)-4-THIAZOLIDINONE




































 Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (d ppm) of Protons In Hz
1 2.4        3H        singlet            Ar-CH3          -
2 7.01-7.04        2H       doublet            Ar-Ha,a’      Jaa’=7.9
3 7.22-7.26        2H       multiplet            Ar-Hc,j          -
4 7.35-7.44        1H       multiplet            Ar-Hh          -
5 7.48-7.53        4H       multiplet            Ar-Hb,b’          -
           Ar-Hd,d’          -
6 7.68        1H        singlet             -NH          -
7 7.76-7.79        2H       doublet            Ar-He,e’      Jee’=8.1
8 7.97-8.0        1H       doublet            Ar-Hk       Jkj=7.8
9 8.09        1H        singlet            Ar-Hl          -
10 8.70-8.71        1H       doublet            Ar-Hg          -

































































m/z = 150 (m+2)
m/z = 137 (m-2)
m/z = 107 (m+2)
m/z = 92 (m+2)
m/z = 244 (m+2)
m/z = 381 (m+2)
m/z = 450 (m+2)

















SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-5-(1’,N-
P H E N Y L - 3 ’ - â - P Y R I D Y L - P Y R A Z O L - 4 ’ - Y L - M E T H I N O ) - 4 -
THIAZOLIDINONES
[A] Synthesis of 3-Acetyl pyridine phenyl hydrazone
See, Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-â-pyridyl-4-fromyl pyrazole
See, Part-I, Section-I (B).
[C] Synthesis of 2-(p-Tolylimino)-5-(1’,N-phenyl-3’-â-pyridyl-pyrazol-4’-yl-
methino)-4-thiazolidinone
To a well stirred solution of 1N-Phenyl-3-â-pyridyl-4-fromyl-pyrazole (2.65gm,
0.01M) and p-Tolylimino-5H-4-thiazolidinone and fused sodium acetate (1.64 g, 0.02M)
was refluxed in glacial acetic acid on oil bath for 12 hrs, cooled and poured into ice
cold water. Crude was isolated and treated with sodium bisulphide. The solid thus
obtained was filtered, washed, dried and crystallised from DMF. Yield,62%, m.p.222oC.
(C25H19N5OS; Found : C,75.33%; H, 4.77%; N, 15.99%; Requires : C, 75.36%; H,
4.81%; N, 16.01%).
Similarly, other substituted chalcones have prepared. The physical data are
recorded in Table No. 13.
[D] Antimicrobial activity of   2-Aryl-5-(1’,N-phenyl-3’-â-pyridyl-pyrazol-4’-
yl-methino)-4-thiazolidinones
Antimicrobial testing was carried out as described in Part-I, Section-II (C). The
zone of inhibition of the test solution are recorded in Graphical Chart No. 13.
Antitubercular  screening of the compounds of type(XV) were carried out by
TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-II
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Rv >6.25 16 - "
RKP-59 295727 4-CH3-C6H4- Alamar H37Rv >6.25 0 - "
RKP-60 295728 2-OCH3-C6H4- Alamar H37Rv >6.25 11 - "
RKP-61 295729 4-OCH3-C6H4- Alamar H37Rv >6.25 0 - "
RKP-62 295730 4-NO2-C6H4- Alamar H37Rv >6.25 89 - "
RKP-63 295731 3,4(Cl)2-C6H3- Alamar H37Rv >6.25 32 - "
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